<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>115</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">115</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alimi, M.</style></author><author><style face="normal" font="default" size="100%">Gaillard, P.</style></author><author><style face="normal" font="default" size="100%">Camus, V.</style></author><author><style face="normal" font="default" size="100%">El-Hage, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Alimi, Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France. E-mail: michael.alimi@ymail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment of tardive dyskinesia: A systematic review (1997-2011)</style></title></titles><pages><style face="normal" font="default" size="100%">160-173</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">(Alimi, Gaillard, Camus, El-Hage) Clinique Psychiatrique Universitaire, CHRU de Tours, France</style></number><edition><style face="normal" font="default" size="100%">3</style></edition><keywords><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">brain depth stimulation</style></keyword><keyword><style face="normal" font="default" size="100%">clinical effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">extrapyramidal symptom/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">parkinsonism/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">peripheral neuropathy/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">*tardive dyskinesia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*tardive dyskinesia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">*tardive dyskinesia/th [Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">acetazolamide/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">acetazolamide/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">alpha tocopherol/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">alpha tocopherol/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">amantadine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">amantadine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">branched chain amino acid/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">branched chain amino acid/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">etiracetam/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">etiracetam/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Ginkgo biloba extract/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">Ginkgo biloba extract/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">icosapentaenoic acid/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">icosapentaenoic acid/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">melatonin/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">melatonin/do [Drug Dose]</style></keyword><keyword><style face="normal" font="default" size="100%">melatonin/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">mianserin/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">mianserin/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">naltrexone/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">naltrexone/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*neuroleptic agent/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">*neuroleptic agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">phenylalanine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">phenylalanine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">piracetam/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">piracetam/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">pyridoxine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">pyridoxine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">pyridoxine/do [Drug Dose]</style></keyword><keyword><style face="normal" font="default" size="100%">pyridoxine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">thiamine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">thiamine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">trazodone/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">trazodone/dt [Drug Therapy]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">Spain</style></pub-location><publisher><style face="normal" font="default" size="100%">University of Zaragoza (Avda. San Juan Bosco 15, P.O. Box 6029, Zaragoza 50009, Spain)</style></publisher><isbn><style face="normal" font="default" size="100%">0213-6163</style></isbn><abstract><style face="normal" font="default" size="100%">Background and Objectives: Tardive dyskinesia (TD) is a frequent and incapacitating side effect of first-generation antipsychotics. Although second-generation antipsychotics (SGAs) seem to be associated with a decreased risk of TD, it remains a severe, unresolved iatrogenic condition. Moreover, there is no commonly accepted effective treatment for TD. We conducted a systematic review of the literature to assess evidence regarding the effectiveness of different therapeutic interventions for TD. Methods: We performed a systematic review focussing exclusively on randomised controlled trials (RCTs). We searched the MEDLINE database (1997 to 2011) using the keyword &quot;tardive dyskinesia&quot; within the &quot;title&quot; search field. Twenty-six RCTs were included. Based on the evidence from RCTs, we built a decision tree that healthcare professionals can use to choose an effective therapeutic intervention for TD. Results: Four therapeutic interventions were found to be effective in TD (vitamin B6, ginkgo biloba, branched-chain amino acids, and piracetam). Conclusions: Patients with TD could benefit from the therapeutic interventions supported by the data accumulated from RCTs.</style></abstract><notes><style face="normal" font="default" size="100%">European Journal of Psychiatry</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://scielo.isciii.es/pdf/ejpen/v27n3/original2.pdf</style></url><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013656502</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>98</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">98</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Annane, D.</style></author><author><style face="normal" font="default" size="100%">Timsit, J. F.</style></author><author><style face="normal" font="default" size="100%">Megarbane, B.</style></author><author><style face="normal" font="default" size="100%">Martin, C.</style></author><author><style face="normal" font="default" size="100%">Misset, B.</style></author><author><style face="normal" font="default" size="100%">Mourvillier, B.</style></author><author><style face="normal" font="default" size="100%">Siami, S.</style></author><author><style face="normal" font="default" size="100%">Chagnon, J. L.</style></author><author><style face="normal" font="default" size="100%">Constantin, J. M.</style></author><author><style face="normal" font="default" size="100%">Petitpas, F.</style></author><author><style face="normal" font="default" size="100%">Souweine, B.</style></author><author><style face="normal" font="default" size="100%">Amathieu, R.</style></author><author><style face="normal" font="default" size="100%">Forceville, X.</style></author><author><style face="normal" font="default" size="100%">Charpentier, C.</style></author><author><style face="normal" font="default" size="100%">Tesnière, A.</style></author><author><style face="normal" font="default" size="100%">Chastre, J.</style></author><author><style face="normal" font="default" size="100%">Bohe, J.</style></author><author><style face="normal" font="default" size="100%">Colin, G.</style></author><author><style face="normal" font="default" size="100%">Cariou, A.</style></author><author><style face="normal" font="default" size="100%">Renault, A.</style></author><author><style face="normal" font="default" size="100%">Brun-Buisson, C.</style></author><author><style face="normal" font="default" size="100%">Bellissant, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Recombinant human activated protein C for adults with septic shock: a randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">American journal of respiratory and critical care medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American journal of respiratory and critical care medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1091-7</style></pages><volume><style face="normal" font="default" size="100%">187</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Fludrocortisone [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrocortisone [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Protein C [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Safety-Based Drug Withdrawals</style></keyword><keyword><style face="normal" font="default" size="100%">Shock, Septic [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00876948</style></accession-num><abstract><style face="normal" font="default" size="100%">RATIONALE: A decade after drotrecogin alfa (activated) (DAA) was released on the market worldwide, its benefit-to-risk ratio remains a matter of debate. OBJECTIVES: The current investigator-led trial was designed to evaluate the efficacy and safety of DAA, in combination with low-dose steroids, in adults with persistent septic shock. METHODS: This was a multicenter (24 intensive care units), placebo-controlled, double-blind, 2 × 2 factorial design trial in which adults with persistent septic shock and no contraindication to DAA were randomly assigned to DAA alone (24 μg/kg/h for 96 h), hydrocortisone and fludrocortisone alone, their respective combinations, or their respective placebos. Primary outcome was mortality rate on Day 90. MEASUREMENTS AND MAIN RESULTS: On October 25, 2011, the trial was suspended after the withdrawal from the market of DAA. The Scientific Committee decided to continue the trial according to a two parallel group design comparing low-dose steroids with their placebos and to analyze the effects of DAA on patients included before trial suspension. At the time trial was suspended, 411 patients had been recruited, 208 had received DAA, and 203 had received its placebo. There was no significant interaction between DAA and low-dose steroids (P = 0.47). On Day 90, there were 99 deaths (47.6%) among the 208 patients receiving DAA and 94 deaths (46.3%) among the 203 patients receiving placebo (P = 0.79). There was no evidence of a difference between DAA and its placebo for any secondary outcomes or serious adverse events. CONCLUSIONS: In adults with established and severe septic shock, DAA showed no evidence of benefit or harm. Clinical trial registered with www.clinicaltrials.gov (NCT00625209).</style></abstract><work-type><style face="normal" font="default" size="100%">Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov&apos;t</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/948/CN-00876948/frame.html</style></url><url><style face="normal" font="default" size="100%">http://www.atsjournals.org/doi/abs/10.1164/rccm.201211-2020OC?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed&amp;</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">Pubmed 23525934</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1164/rccm.201211-2020OC</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>84</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">84</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Apostolova Liana, G.</style></author><author><style face="normal" font="default" size="100%">Babakchanian, Sona</style></author><author><style face="normal" font="default" size="100%">Hwang Kristy, S.</style></author><author><style face="normal" font="default" size="100%">Green Amity, E.</style></author><author><style face="normal" font="default" size="100%">Zlatev, Dimitar</style></author><author><style face="normal" font="default" size="100%">Chou, Yi-Yu</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI Donepezil/Vitamin E Study</style></title><secondary-title><style face="normal" font="default" size="100%">Alzheimer disease and associated disorders</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Alzheimer disease and associated disorders</style></full-title></periodical><pages><style face="normal" font="default" size="100%">174-81</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Sr-dementia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">Cn-00872976</style></accession-num><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/976/CN-00872976/frame.html</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>116</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">116</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arango, C.</style></author><author><style face="normal" font="default" size="100%">Garibaldi, G.</style></author><author><style face="normal" font="default" size="100%">Marder, S. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.R. Marder, West Los Angeles VA Healthcare Center, Building 210, 11301 Wilshire Blvd, Los Angeles, CA 90073, United States. E-mail: marder@ucla.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pharmacological approaches to treating negative symptoms: A review of clinical trials</style></title></titles><pages><style face="normal" font="default" size="100%">346-352</style></pages><volume><style face="normal" font="default" size="100%">150</style></volume><number><style face="normal" font="default" size="100%">(Arango) Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Maranon, IiSGM, School of Medicine, Universidad Complutense, CIBERSAM, Madrid, Spain</style></number><edition><style face="normal" font="default" size="100%">2-3</style></edition><keywords><keyword><style face="normal" font="default" size="100%">add on therapy</style></keyword><keyword><style face="normal" font="default" size="100%">adjuvant therapy</style></keyword><keyword><style face="normal" font="default" size="100%">clinical effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">clinical evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">disease exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose comparison</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">low drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">*negative syndrome/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">positive syndrome/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">3 (2,4 dimethoxybenzylidene)anabaseine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">3 (2,4 dimethoxybenzylidene)anabaseine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">amisulpride/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">amisulpride/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">amisulpride/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressant agent/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressant agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">armodafinil/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">armodafinil/do [Drug Dose]</style></keyword><keyword><style face="normal" font="default" size="100%">armodafinil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">asenapine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">asenapine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">asenapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">atypical antipsychotic agent/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">atypical antipsychotic agent/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">atypical antipsychotic agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">cholinergic receptor stimulating agent/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">cholinergic receptor stimulating agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">dopamine receptor stimulating agent/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">dopamine receptor stimulating agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">fluoxetine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">fluoxetine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">fluphenazine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">fluphenazine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">fluphenazine/do [Drug Dose]</style></keyword><keyword><style face="normal" font="default" size="100%">fluphenazine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">glutamate receptor agonist/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">glutamate receptor agonist/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">glycine receptor agonist/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">glycine receptor agonist/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">glycine receptor agonist/do [Drug Dose]</style></keyword><keyword><style face="normal" font="default" size="100%">glycine receptor agonist/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol/do [Drug Dose]</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">lisdexamfetamine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">lisdexamfetamine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">minocycline/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">minocycline/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">modafinil/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">modafinil/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">modafinil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">nicotinic agent/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">nicotinic agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">ritanserin/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">ritanserin/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">selegiline/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">selegiline/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">tc 5619/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">tc 5619/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">trazodone/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">trazodone/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">unindexed drug</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">Netherlands</style></pub-location><publisher><style face="normal" font="default" size="100%">Elsevier (P.O. Box 211, Amsterdam 1000 AE, Netherlands)</style></publisher><isbn><style face="normal" font="default" size="100%">0920-9964</style></isbn><abstract><style face="normal" font="default" size="100%">Clinical trials of pharmacological agents targeting negative symptoms in schizophrenia are reviewed. The focus is on trials that occurred in patients who were stable on an antipsychotic medication at entry to the trial. A small number of trials compared antipsychotics as monotherapy for negative symptoms. Although the data supporting amisulpride for negative symptoms is promising the trials have limitations and it is plausible that the advantages of amisulpride over placebo may result from effects on secondary negative symptoms. Among available agents, antidepressant medications may have effects in negative symptoms. Other promising agents include minocycline, glutamatergic agents, and alpha-7 nicotinic agents. More than 15 active trials are currently underway to evaluate new treatments for negative symptoms. 2013.</style></abstract><notes><style face="normal" font="default" size="100%">Schizophrenia Research</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013675951</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>72</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">72</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Atri, A.</style></author><author><style face="normal" font="default" size="100%">Molinuevo, J. L.</style></author><author><style face="normal" font="default" size="100%">Lemming, O.</style></author><author><style face="normal" font="default" size="100%">Wirth, Y.</style></author><author><style face="normal" font="default" size="100%">Pulte, I.</style></author><author><style face="normal" font="default" size="100%">Wilkinson, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Memantine in patients with Alzheimer&apos;s disease receiving donepezil: New analyses of efficacy and safety for combination therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Alzheimer&apos;s Research and Therapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Alzheimer&apos;s Research and Therapy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">aged // agitation // Alzheimer disease/dt [Drug Therapy] // article // brain function // cognition // confusion/si [Side Effect] // controlled study // depression/si [Side Effect] // diarrhea/si [Side Effect] // dizziness/si [Side Effect] // double blin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00911850</style></accession-num><abstract><style face="normal" font="default" size="100%">Introduction. Memantine and cholinesterase inhibitors potentially offer additional benefits in Alzheimer&apos;s disease (AD) when used together. This study assessed the efficacy and safety of combination treatment with memantine added to stable donepezil in patients with moderate to severe AD, and in a subset with moderate AD. Methods. Post hoc meta-analyses of data combined from two 24-week, randomised, double-blind, placebo-controlled trials of memantine 20 mg/day versus placebo, added to a stable cholinesterase inhibitor, were conducted. Data were included for all patients receiving donepezil 10 mg/day with Mini-Mental State Examination (MMSE) scores &lt; 20 (n = 510). Efficacy was assessed using measures of cognition, function, and global status. Furthermore, marked clinical worsening, defined as concurrent deterioration from baseline in the three main efficacy domains, and safety, measured by treatment-emergent adverse events, were assessed. Analyses were performed for patients with moderate to severe AD (MMSE 5-19; MOD-SEV subgroup), and also for patients with moderate AD (MMSE 10-19; MOD subgroup; n = 367). Results: At week 24, in the MOD-SEV subgroup, patients receiving memantine added to donepezil significantly outperformed those receiving placebo added to donepezil in measures of cognition (P &lt; 0.0001), function (P = 0.02), and global status (P = 0.010), with standardised mean differences (SMDs) of 0.36, 0.21, and 0.23, respectively (all last observation carried forward). Similarly, in the MOD subgroup, significant benefits were observed for cognition (P = 0.008), function (P = 0.04) and global status (P = 0.008), with SMDs of 0.28, 0.21, and 0.28, respectively. Significantly fewer patients receiving memantine added to donepezil showed marked clinical worsening than those receiving placebo added to donepezil, in both subgroups (MOD-SEV: 8.7% versus 20.4%, P = 0.0002; MOD: 5.9% versus 15.0%, P = 0.006). The incidence of adverse events was similar between treatment groups. Conclusions: These results support and extend previous evidence that combination treatment with memantine added to stable donepezil in patients with moderate AD, and in those with moderate to severe AD, is associated with significant benefits in reducing 24-week decline in cognition, function and global status. Combination treatment produces substantially reduced rates of marked clinical worsening, has good safety and tolerability, and generates effect sizes that are both statistically significant and clinically meaningful. 2013 Atri et al.; licensee BioMed Central Ltd.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/850/CN-00911850/frame.html</style></url><url><style face="normal" font="default" size="100%">http://alzres.com/content/pdf/alzrt160.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3516616717/Atri-2013-Memantine in patient.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/alzrt160</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>111</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">111</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ballesteros, J.</style></author><author><style face="normal" font="default" size="100%">Guillen, V.</style></author><author><style face="normal" font="default" size="100%">Zabala, A.</style></author><author><style face="normal" font="default" size="100%">Santos, B.</style></author><author><style face="normal" font="default" size="100%">Rueda, J. R.</style></author><author><style face="normal" font="default" size="100%">Sola, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. Ballesteros, University of the Basque Country, UPV/EHU, Leioa, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical outcomes in schizophrenia treated with donepezil in combination with antipsychotics</style></title><tertiary-title><style face="normal" font="default" size="100%">ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106&#xD;(var.pagings)</style></tertiary-title></titles><pages><style face="normal" font="default" size="100%">A542</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">(Ballesteros, Guillen, Zabala, Santos, Rueda) University of the Basque Country, UPV/EHU, Leioa, Spain</style></number><edition><style face="normal" font="default" size="100%">7</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*schizophrenia</style></keyword><keyword><style face="normal" font="default" size="100%">Positive and Negative Syndrome Scale</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">positive syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">crossover procedure</style></keyword><keyword><style face="normal" font="default" size="100%">sample size</style></keyword><keyword><style face="normal" font="default" size="100%">effect size</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">adjuvant therapy</style></keyword><keyword><style face="normal" font="default" size="100%">negative syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">enhancer region</style></keyword><keyword><style face="normal" font="default" size="100%">*donepezil</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">Elsevier Ltd</style></publisher><isbn><style face="normal" font="default" size="100%">1098-3015</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: To assess the efficacy of a cognitive enhancer, donepezil, as an adjuvant treatment to antipsychotics on clinical outcomes of schizophrenia. Methods: Systematic review with meta-analysis to obtain appropriate evidence from randomized clinical trials (RCTs) on the efficacy of donepezil plus antipsychotics versus placebo plus antipsychotics in patients diagnosed with schizophrenia for the following outcomes: General psychopathology, positive/negative symptoms, and depressive symptoms. Effect size estimates corrected for small sample size trials (Hedges&apos; g) were calculated for parallel trials and cross-over trials. Negative values for Hedges&apos; g denote an effect favouring the combined treatment. When needed, values for the cross-over correlation were imputed from available individual data to obtain the Hedges&apos; g estimates. The individual estimates were pooled with a random-effects meta-analysis. Results: Seven trials (4 cross-over, 3 parallel) were included. Four trials provided data on the Positive and Negative Syndrome Scale (PANSS) for total and general psychopathology scores. Three trials provided data for PANSS positive scores and 5 trials provided data for PANSS negative scores. Three trials provided data on depression scores. The combined treatment did not show differences in any of the assessed outcomes: PANSS total scores (g = -0.57, 95% CI = -2.11 to 0.96 I2 = 67%); PANSS General Psychopathology scores (g = -0.20, 95% CI = -0.74 to 0.34 I2 = 0%); PANSS positive symptoms (g = -0.06, 95% CI = -0.73 to 0.60, I2 = 0%); PANSS negative symptoms (g = -0.43, 95% CI = -1.98 to 1.12, I2 = 86%); depression scores (g = -0.35, 95% CI = -1.20 to 0.49, I2 = 0%). Conclusions: The combination of donepezil with antipsychotic treatment does not improve clinical outcomes in schizophrenia.</style></abstract><notes><style face="normal" font="default" size="100%">Value in Health</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=71233444</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>102</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">102</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bao, T.</style></author><author><style face="normal" font="default" size="100%">Cai, L.</style></author><author><style face="normal" font="default" size="100%">Giles, J. T.</style></author><author><style face="normal" font="default" size="100%">Gould, J.</style></author><author><style face="normal" font="default" size="100%">Tarpinian, K.</style></author><author><style face="normal" font="default" size="100%">Betts, K.</style></author><author><style face="normal" font="default" size="100%">Medeiros, M.</style></author><author><style face="normal" font="default" size="100%">Jeter, S.</style></author><author><style face="normal" font="default" size="100%">Tait, N.</style></author><author><style face="normal" font="default" size="100%">Chumsri, S.</style></author><author><style face="normal" font="default" size="100%">Armstrong, D. K.</style></author><author><style face="normal" font="default" size="100%">Tan, M.</style></author><author><style face="normal" font="default" size="100%">Folkerd, E.</style></author><author><style face="normal" font="default" size="100%">Dowsett, M.</style></author><author><style face="normal" font="default" size="100%">Singh, H.</style></author><author><style face="normal" font="default" size="100%">Tkaczuk, K.</style></author><author><style face="normal" font="default" size="100%">Stearns, V.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors</style></title><secondary-title><style face="normal" font="default" size="100%">Breast Cancer Research and Treatment</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Breast Cancer Research and Treatment</style></full-title></periodical><pages><style face="normal" font="default" size="100%">167-174</style></pages><volume><style face="normal" font="default" size="100%">138</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">acupuncture // adult // aged // article // breast cancer/dt [Drug Therapy] // cancer chemotherapy // cancer staging // clinical article // clinical effectiveness // controlled study // disease association // double blind procedure // drug safety // estr</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00911654</style></accession-num><abstract><style face="normal" font="default" size="100%">Up to 50 % of women receiving aromatase inhibitor (AI) complain of AI-associated musculoskeletal symptoms (AIMSS) and 15 % discontinue treatment. We conducted a randomized, sham-controlled trial to evaluate whether acupuncture improves AIMSS and to explore potential mechanisms. Postmenopausal women with early stage breast cancer, experiencing AIMSS were randomized to eight weekly real or sham acupuncture sessions. We evaluated changes in the Health Assessment Questionnaire Disability Index (HAQ-DI) and pain visual analog scale (VAS) following the intervention compared to baseline. Serum estradiol, beta-endorphin, and proinflammatory cytokine concentrations were measured pre and post-intervention. We enrolled 51 women of whom 47 were evaluable, including 23 randomized to real and 24 to sham acupuncture. Baseline characteristics were balanced between groups with the exception of a higher HAQ-DI score in the real acupuncture group (p = 0.047). We did not observe a statistically significant difference in reduction of HAQ-DI (p = 0.30) or VAS (p = 0.31) between the two groups. Following eight weekly treatments, we observed a statistically significant reduction of IL-17 (p &lt;= 0.009) in both groups. No significant modulation was seen in estradiol, beta-endorphin, or other proinflammatory cytokine concentrations in either group. We did not observe a significant difference in AIMSS changes between real and sham acupuncture. As sham acupuncture used in this study may not be equivalent to placebo, further studies with a non-acupuncture arm may be required to establish whether acupuncture is beneficial for the treatment of AIMSS. 2013 Springer Science+Business Media New York.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/654/CN-00911654/frame.html</style></url><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594526/pdf/nihms443854.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://4146382462/Bao-2013-A dual-center random.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s10549-013-2427-z</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>119</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">119</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brondino, N.</style></author><author><style face="normal" font="default" size="100%">De Silvestri, A.</style></author><author><style face="normal" font="default" size="100%">Re, S.</style></author><author><style face="normal" font="default" size="100%">Lanati, N.</style></author><author><style face="normal" font="default" size="100%">Thiemann, P.</style></author><author><style face="normal" font="default" size="100%">Verna, A.</style></author><author><style face="normal" font="default" size="100%">Emanuele, E.</style></author><author><style face="normal" font="default" size="100%">Politi, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">N. Brondino, Department of Brain and Behavioral Sciences, Section of Psychiatry, University of Pavia, Via Bassi 21, 27100 Pavia, Italy. E-mail: natascia.brondino@libero.it</style></auth-address><titles><title><style face="normal" font="default" size="100%">A systematic review and meta-analysis of ginkgo biloba in neuropsychiatric disorders: From ancient tradition to modern-day medicine</style></title></titles><volume><style face="normal" font="default" size="100%">2013</style></volume><number><style face="normal" font="default" size="100%">(Brondino, Re, Verna, Emanuele, Politi) Department of Brain and Behavioral Sciences, Section of Psychiatry, University of Pavia, Via Bassi 21, 27100 Pavia, Italy</style></number><keywords><keyword><style face="normal" font="default" size="100%">Abnormal Involuntary Movement Scale</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">attention deficit disorder/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">autism/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Global Impression scale</style></keyword><keyword><style face="normal" font="default" size="100%">cocaine dependence/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">cognition</style></keyword><keyword><style face="normal" font="default" size="100%">daily life activity</style></keyword><keyword><style face="normal" font="default" size="100%">dementia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">DSM-IV-TR</style></keyword><keyword><style face="normal" font="default" size="100%">generalized anxiety disorder/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Ginkgo biloba</style></keyword><keyword><style face="normal" font="default" size="100%">Hamilton Anxiety Scale</style></keyword><keyword><style face="normal" font="default" size="100%">Hamilton scale</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">*mental disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">negative syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">positive syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">Sansevieria</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">tardive dyskinesia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Ginkgo biloba extract/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">*Ginkgo biloba extract/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">*Ginkgo biloba extract/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">*Ginkgo biloba extract/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">*Ginkgo biloba extract/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Ginkgo biloba extract/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">methylphenidate/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">methylphenidate/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*neuroleptic agent/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">*neuroleptic agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*neuroleptic agent/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">piracetam/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">piracetam/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/dt [Drug Therapy]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">United States</style></pub-location><publisher><style face="normal" font="default" size="100%">Hindawi Publishing Corporation (410 Park Avenue, 15th Floor, 287 pmb, New York NY 10022, United States)</style></publisher><isbn><style face="normal" font="default" size="100%">1741-427X</style></isbn><abstract><style face="normal" font="default" size="100%">Ginkgo biloba (Gb) has demonstrated antioxidant and vasoactive properties as well as clinical benefits in several conditions such as ischemia, epilepsy, and peripheral nerve damage. Additionally, Gb is supposed to act as potential cognitive enhancer in dementia. So far, several trials have been conducted to investigate the potential effectiveness of Gb in neuropsychiatric conditions. However, the results of these studies remain controversial. We conducted a systematic review and a meta-analysis of three randomised controlled trials in patients with schizophrenia and eight randomised controlled trials in patients with dementia. Gb treatment reduced positive symptoms in patients with schizophrenia and improved cognitive function and activities of daily living in patients with dementia. No effect of Gb on negative symptoms in schizophrenic patients was found. The general lack of evidence prevents drawing conclusions regarding Gb effectiveness in other neuropsychiatric conditions (i.e., autism, depression, anxiety, attention-deficit hyperactivity disorder, and addiction). Our data support the use of Gb in patients with dementia and as an adjunctive therapy in schizophrenic patients. 2013 Natascia Brondino et al.</style></abstract><notes><style face="normal" font="default" size="100%">Evidence-based Complementary and Alternative Medicine</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013393900</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>107</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">107</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cannon, Christopher E.</style></author><author><style face="normal" font="default" size="100%">Puri, Vanita</style></author><author><style face="normal" font="default" size="100%">Vivian, Jeffrey A.</style></author><author><style face="normal" font="default" size="100%">Egbertson, Melissa S.</style></author><author><style face="normal" font="default" size="100%">Eddins, Donnie</style></author><author><style face="normal" font="default" size="100%">Uslaner, Jason M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The nicotinic alpha7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys</style></title><secondary-title><style face="normal" font="default" size="100%">Neuropharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuropharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">191-6</style></pages><volume><style face="normal" font="default" size="100%">64</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Behavior, Animal/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">*Benzylidene Compounds/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cholinesterase Inhibitors/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cholinesterase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/et [Etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">*Cognition Disorders/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Evaluation, Preclinical/mt [Methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Excitatory Amino Acid Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Indans/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Indans/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Ketamine</style></keyword><keyword><style face="normal" font="default" size="100%">Macaca mulatta</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Targeted Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Nicotinic Agonists/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">*Nicotinic Agonists/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Nootropic Agents/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">*Nootropic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperidines/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperidines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Psychomotor Performance/de [Drug Effects]</style></keyword><keyword><style face="normal" font="default" size="100%">*Pyridines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, N-Methyl-D-Aspartate/ai [Antagonists &amp; Inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Nicotinic/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, Nicotinic/me [Metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">*Schizophrenia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Schizophrenia/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">alpha7 Nicotinic Acetylcholine Receptor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">England</style></pub-location><publisher><style face="normal" font="default" size="100%">Merck Research Laboratories 44E-200, 770 Sumneytown Pike, West Point, PA 19486, USA. christopher_cannon@merck.com</style></publisher><isbn><style face="normal" font="default" size="100%">1873-7064</style></isbn><abstract><style face="normal" font="default" size="100%">The cognitive deficits associated with schizophrenia are recognized as a core component of the disorder, yet there remain no available therapeutics to treat these symptoms of the disease. As a result, there is a need for establishing predictive preclinical models to identify the therapeutic potential of novel compounds. In the present study, rhesus monkeys were trained in the object retrieval-detour task, which is dependent on the prefrontal cortex, a brain region implicated in the cognitive deficits associated with schizophrenia. The NMDA receptor antagonist ketamine significantly impaired performance without affecting measures of motor or visuospatial abilities. Pre-treatment with the nicotinic alpha7 agonist GTS-21 (0.03 mg/kg) significantly attenuated the ketamine-induced impairment, consistent with reports from clinical trials suggesting that nicotinic alpha7 receptor agonism has pro-cognitive potential in clinical populations. In contrast, pretreatment with the acetylcholinesterase inhibitor donepezil failed to reverse the ketamine-induced impairment, consistent with studies showing a lack of pro-cognitive effects in patients with schizophrenia. These data suggest that the ketamine-impaired object retrieval-detour task could provide a model with improved predictive validity for drug development, and confirm the need for additional efforts in back-translation. This article is part of a Special Issue entitled &apos;Cognitive Enhancers&apos;. Copyright 2012 Elsevier Ltd. All rights reserved.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=medl&amp;NEWS=N&amp;AN=22659472</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>127</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">127</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cannon, C. E.</style></author><author><style face="normal" font="default" size="100%">Puri, V.</style></author><author><style face="normal" font="default" size="100%">Vivian, J. A.</style></author><author><style face="normal" font="default" size="100%">Egbertson, M. S.</style></author><author><style face="normal" font="default" size="100%">Eddins, D.</style></author><author><style face="normal" font="default" size="100%">Uslaner, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C.E. Cannon, Merck Research Laboratories 44E-200, 770 Sumneytown Pike, West Point, PA 19486, United States. E-mail: christopher_cannon@merck.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">The nicotinic alpha7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys</style></title></titles><pages><style face="normal" font="default" size="100%">191-196</style></pages><volume><style face="normal" font="default" size="100%">64</style></volume><number><style face="normal" font="default" size="100%">(Cannon, Puri, Vivian, Egbertson, Eddins, Uslaner) Merck Research Laboratories 44E-200, 770 Sumneytown Pike, West Point, PA 19486, United States</style></number><keywords><keyword><style face="normal" font="default" size="100%">animal experiment</style></keyword><keyword><style face="normal" font="default" size="100%">animal model</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">cognition</style></keyword><keyword><style face="normal" font="default" size="100%">*cognitive defect/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">mental performance</style></keyword><keyword><style face="normal" font="default" size="100%">mental task</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia</style></keyword><keyword><style face="normal" font="default" size="100%">*3 (2,4 dimethoxybenzylidene)anabaseine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">*3 (2,4 dimethoxybenzylidene)anabaseine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*3 (2,4 dimethoxybenzylidene)anabaseine/im [Intramuscular Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">acetylcholinesterase/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">bungarotoxin receptor/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/po [Oral Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">ketamine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">United Kingdom</style></pub-location><publisher><style face="normal" font="default" size="100%">Elsevier Ltd (Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom)</style></publisher><isbn><style face="normal" font="default" size="100%">0028-3908</style></isbn><abstract><style face="normal" font="default" size="100%">The cognitive deficits associated with schizophrenia are recognized as a core component of the disorder, yet there remain no available therapeutics to treat these symptoms of the disease. As a result, there is a need for establishing predictive preclinical models to identify the therapeutic potential of novel compounds. In the present study, rhesus monkeys were trained in the object retrieval-detour task, which is dependent on the prefrontal cortex, a brain region implicated in the cognitive deficits associated with schizophrenia. The NMDA receptor antagonist ketamine significantly impaired performance without affecting measures of motor or visuospatial abilities. Pre-treatment with the nicotinic alpha7 agonist GTS-21 (0.03 mg/kg) significantly attenuated the ketamine-induced impairment, consistent with reports from clinical trials suggesting that nicotinic alpha7 receptor agonism has pro-cognitive potential in clinical populations. In contrast, pretreatment with the acetylcholinesterase inhibitor donepezil failed to reverse the ketamine-induced impairment, consistent with studies showing a lack of pro-cognitive effects in patients with schizophrenia. These data suggest that the ketamine-impaired object retrieval-detour task could provide a model with improved predictive validity for drug development, and confirm the need for additional efforts in back-translation. This article is part of a Special Issue entitled &apos;Cognitive Enhancers&apos;. 2012 Elsevier Ltd. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Neuropharmacology</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed10&amp;NEWS=N&amp;AN=2012551273</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>130</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">130</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cannon, Christopher E.</style></author><author><style face="normal" font="default" size="100%">Puri, Vanita</style></author><author><style face="normal" font="default" size="100%">Vivian, Jeffrey A.</style></author><author><style face="normal" font="default" size="100%">Egbertson, Melissa S.</style></author><author><style face="normal" font="default" size="100%">Eddins, Donnie</style></author><author><style face="normal" font="default" size="100%">Uslaner, Jason M.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Akhondzadeh, Alkondon Alkondon Arendash Arnsten Buccafusco Buchanan Burdick Carter Chouinard Dalack Diamond Diamond Diamond Dias Dickinson Dyer Elvevag Ettrup Freedman Freedman Friedman Geyer Geyer Goff Gopalakrishnan Gotti Jentsch Jentsch Jentsch Keefe Lahti Lewis Lindenmayer Livingstone Maier Marchi Marder Markou Marutle Matsuoka McGrath Millan Minzenberg Olincy Peng Puchacz Ripoll Roitberg Rousseau Rowland Schneider Schneider Severance Summers Taylor Taylor Tregellas van Os Wallace Wilkinson Williams Young Zhao Zoltewicz</style></author></secondary-authors></contributors><auth-address><style face="normal" font="default" size="100%">Cannon, Christopher E.: Merck Research Laboratories, 44E-200, 770 Sumneytown Pike, West Point, PA, US, 19486, christopher.cannon@gmail.com&#xD;Cannon, Christopher E.: christopher_cannon@merck.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">The nicotinic 7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys</style></title><tertiary-title><style face="normal" font="default" size="100%">International Journal of Neuropharmacology</style></tertiary-title></titles><pages><style face="normal" font="default" size="100%">191-196</style></pages><volume><style face="normal" font="default" size="100%">64</style></volume><number><style face="normal" font="default" size="100%">Akhondzadeh, S., Gerami, M., Noroozian, M., Karamghadiri, N., Ghoreishi, A., Abbasi, S.H., &amp; Rezazadeh, S.A. (2008). A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 328, 1810-1815. http://dx.doi.org/10.1016/j.pnpbp.2008.08.001</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Acetylcholinesterase</style></keyword><keyword><style face="normal" font="default" size="100%">*Cholinergic Drugs</style></keyword><keyword><style face="normal" font="default" size="100%">*Cholinergic Receptors</style></keyword><keyword><style face="normal" font="default" size="100%">*Ketamine</style></keyword><keyword><style face="normal" font="default" size="100%">*Animal Cognition</style></keyword><keyword><style face="normal" font="default" size="100%">Monkeys</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">Netherlands</style></pub-location><publisher><style face="normal" font="default" size="100%">Elsevier Science&#xD;Netherlands</style></publisher><isbn><style face="normal" font="default" size="100%">0028-3908</style></isbn><abstract><style face="normal" font="default" size="100%">The cognitive deficits associated with schizophrenia are recognized as a core component of the disorder, yet there remain no available therapeutics to treat these symptoms of the disease. As a result, there is a need for establishing predictive preclinical models to identify the therapeutic potential of novel compounds. In the present study, rhesus monkeys were trained in the object retrieval-detour task, which is dependent on the prefrontal cortex, a brain region implicated in the cognitive deficits associated with schizophrenia. The NMDA receptor antagonist ketamine significantly impaired performance without affecting measures of motor or visuospatial abilities. Pre-treatment with the nicotinic 7 agonist GTS-21 (0.03 mg/kg) significantly attenuated the ketamine-induced impairment, consistent with reports from clinical trials suggesting that nicotinic 7 receptor agonism has pro-cognitive potential in clinical populations. In contrast, pretreatment with the acetylcholinesterase inhibitor donepezil failed to reverse the ketamine-induced impairment, consistent with studies showing a lack of pro-cognitive effects in patients with schizophrenia. These data suggest that the ketamine-impaired object retrieval-detour task could provide a model with improved predictive validity for drug development, and confirm the need for additional efforts in back-translation. (PsycINFO Database Record (c) 2013 APA, all rights reserved) (journal abstract)</style></abstract><notes><style face="normal" font="default" size="100%">Neuropharmacology&#xD;http://dx.doi.org/10.1016/j.neuropharm.2012.05.003</style></notes><work-type><style face="normal" font="default" size="100%">Psychopharmacology 2580</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=psyc7&amp;NEWS=N&amp;AN=2012-16474-001</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>112</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">112</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cano-Cuenca, N.</style></author><author><style face="normal" font="default" size="100%">Del Pozo, J. E. S. G.</style></author><author><style face="normal" font="default" size="100%">Jordan, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. Jordan, Grupo Neurofarmacologia, Departamento de Ciencias Medicas, Universidad de Castilla-La Mancha, Calle Almansa, 14, Albacete-02008, Spain. E-mail: joaquin.jordan@uclm.es</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evidence for the efficacy of latrepirdine (dimebon) treatment for improvement of cognitive function: A meta-analysis</style></title></titles><pages><style face="normal" font="default" size="100%">155-164</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">(Cano-Cuenca, Jordan) Grupo Neurofarmacologia, Departamento de Ciencias Medicas, Universidad de Castilla-La Mancha, Calle Almansa, 14, Albacete-02008, Spain</style></number><edition><style face="normal" font="default" size="100%">1</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Abnormal Involuntary Movement Scale</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer Disease Assessment Scale</style></keyword><keyword><style face="normal" font="default" size="100%">alzheimer disease assessment scale cognitive subscale</style></keyword><keyword><style face="normal" font="default" size="100%">alzheimer disease cooperative study activities of daily living</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Barnes Akathisia Scale</style></keyword><keyword><style face="normal" font="default" size="100%">Butakina scale</style></keyword><keyword><style face="normal" font="default" size="100%">Calgary Depression Scale</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment tool</style></keyword><keyword><style face="normal" font="default" size="100%">Clinician Interview Based Impression of Change plus Caregiver Imput</style></keyword><keyword><style face="normal" font="default" size="100%">*cognition</style></keyword><keyword><style face="normal" font="default" size="100%">*degenerative disease</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose titration</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Hasegawa scale</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Huntington chorea</style></keyword><keyword><style face="normal" font="default" size="100%">loading drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Mini Mental State Examination</style></keyword><keyword><style face="normal" font="default" size="100%">phase 1 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">phase 3 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">Positive and Negative Syndrome Scale</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">rating scale</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia</style></keyword><keyword><style face="normal" font="default" size="100%">Simpson-Angus Scale</style></keyword><keyword><style face="normal" font="default" size="100%">Unified Huntington Disease Rating Scale</style></keyword><keyword><style face="normal" font="default" size="100%">xerostomia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">*dimebon/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">*dimebon/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">*dimebon/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">*dimebon/do [Drug Dose]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">warfarin/cb [Drug Combination]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><pub-location><style face="normal" font="default" size="100%">Netherlands</style></pub-location><publisher><style face="normal" font="default" size="100%">IOS Press (Nieuwe Hemweg 6B, Amsterdam 1013 BG, Netherlands)</style></publisher><isbn><style face="normal" font="default" size="100%">1387-2877</style></isbn><abstract><style face="normal" font="default" size="100%">Over the last few years, latrepirdine, a demode antihistamine drug, has been proposed to be useful for treating neurodegenerative disorders such as Alzheimer&apos;s and Huntington&apos;s diseases, and more recently schizophrenia. The mechanisms and pharmacological targets that are responsible for the beneficial effects on neurodegenerative diseases remain unknown. But it has been proposed that latrepirdine may modulate several targets including voltage-gate Ca+2 channels, mitochondrial permeability pore transition, or several neurotransmitter receptors. Herein, we present a meta-analysis of randomized controlled trials to ascertain the efficacy and safety of latrepirdine on cognitive function. By doing a search in electronic databases, we found five clinical trials in which the effect of latrepirdine on cognition function has been studied, and this was evaluated using MMSE, ADAS-cog, ADCS-ADL, and NPI scores. Latrepirdine generally presented a good safety profile; it was well tolerated when given alone or in combination with a variety of other drugs. We observed heterogeneous results between trials; latrepirdine failed to exert a significant beneficial effect although it tended to improve cognitive scores. The only significant benefit that we found was for the NPI score in Alzheimer&apos;s disease patients. 2014 A IOS Press and the authors. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Journal of Alzheimer&apos;s Disease</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013704089</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>70</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">70</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Lu, Z.</style></author><author><style face="normal" font="default" size="100%">Zhang, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Ni, X.</style></author><author><style face="normal" font="default" size="100%">Jiang, X.</style></author><author><style face="normal" font="default" size="100%">Xu, H.</style></author><author><style face="normal" font="default" size="100%">Heeramun-Aubeeluck, A.</style></author><author><style face="normal" font="default" size="100%">Hu, Q.</style></author><author><style face="normal" font="default" size="100%">Jin, H.</style></author><author><style face="normal" font="default" size="100%">Davis, J. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania</style></title><secondary-title><style face="normal" font="default" size="100%">Neuropsychiatric Disease and Treatment</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuropsychiatric Disease and Treatment</style></full-title></periodical><pages><style face="normal" font="default" size="100%">839-845</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><keywords><keyword><style face="normal" font="default" size="100%">adult // aged // article // bipolar disorder // clinical article // constipation/si [Side Effect] // controlled study // diarrhea/si [Side Effect] // disease classification // disease severity // double blind procedure // drug blood level // drug dose i</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00905303</style></accession-num><abstract><style face="normal" font="default" size="100%">Introduction: A significant number of mania patients fail to respond to current pharmacotherapy, thereby there is need for novel augmentation strategies. The results of some early studies showed the effectiveness of cholinomimetics in the treatment of mania. One open case series suggested the efficacy of donepezil in the treatment of bipolar disorder. Our aim was to explore whether an oral cholinesterase inhibitor, donepezil, administered during a 4-week treatment period, would benefit patients with acute mania. Methods: We conducted a 4-week double-blind, placebo-controlled trial of donepezil as an adjunctive treatment to lithium in patients with acute mania. Eligible subjects were randomly assigned to receive donepezil or placebo in addition to lithium. Donepezil was started at 5 mg/day, and increased to 10 mg/day in the first week. Patients were rated with the Young Mania Rating Scale (YMRS) and Brief Psychiatric Rating Scale (BPRS) at baseline, day 1, week 1, week 2, and week 4. Results: Out of the 30 patients who were enrolled, 15 were on donepezil and 15 were on placebo. All patients completed the 4-week trial. On the first day, there was a difference of 1.97 units on the psychomotor symptoms scale of the YMRS in the donepezil group as compared to the placebo group (t = 2.39, P = 0.02). There was a difference of 0.57 units (t = 2.09, P = 0.04) in the speech item and a difference of 0.29 units in the sexual interest item (t = 2.11, P = 0.04) in the donepezil group as compared to the placebo group. The total YMRS difference on the first day approached the conventional significance level (1.97 units, t = 1.84, P = 0.07). Over the course of 4 weeks, we failed to find that donepezil produced any significant difference in the YMRS (6.71 units difference, t = -1.44, P = 0.16) or the BPRS scale (1.29 units difference, t = -0.33, P = 0.75) as compared to placebo. Ten subjects (66.67%) in both groups met the criteria for clinical response (Fisher&apos;s exact P = 1.00). Five subjects (33.33%) in the donepezil group met the criteria for clinical remission while nine subjects (60.00%) in the placebo group met the remission criteria (Fisher&apos;s exact P = 0.27). Conclusion: Use of the oral anticholinergic donepezil had some benefit in the augmentation of lithium treatment on the first day, but did not provide any significant benefits in the long-term. 2013 Chen et al, publisher and licensee Dove Medical Press Ltd.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/303/CN-00905303/frame.html</style></url><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688436/pdf/ndt-9-839.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3006968069/Chen-2013-A randomized, 4-week.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.2147/NDT.S40503</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>92</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">92</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chew, E. Y.</style></author><author><style face="normal" font="default" size="100%">SanGiovanni, J. P.</style></author><author><style face="normal" font="default" size="100%">Ferris, F. L.</style></author><author><style face="normal" font="default" size="100%">Wong, W. T.</style></author><author><style face="normal" font="default" size="100%">Agron, E.</style></author><author><style face="normal" font="default" size="100%">Clemons, T. E.</style></author><author><style face="normal" font="default" size="100%">Sperduto, R.</style></author><author><style face="normal" font="default" size="100%">Danis, R.</style></author><author><style face="normal" font="default" size="100%">Chandra, S. R.</style></author><author><style face="normal" font="default" size="100%">Blodi, B. A.</style></author><author><style face="normal" font="default" size="100%">Domalpally, A.</style></author><author><style face="normal" font="default" size="100%">Elman, M. J.</style></author><author><style face="normal" font="default" size="100%">Antoszyk, A. N.</style></author><author><style face="normal" font="default" size="100%">Ruby, A. J.</style></author><author><style face="normal" font="default" size="100%">Orth, D.</style></author><author><style face="normal" font="default" size="100%">Bressler, S. B.</style></author><author><style face="normal" font="default" size="100%">Fish, G. E.</style></author><author><style face="normal" font="default" size="100%">Hubbard, G. B.</style></author><author><style face="normal" font="default" size="100%">Klein, M. L.</style></author><author><style face="normal" font="default" size="100%">Friberg, T. R.</style></author><author><style face="normal" font="default" size="100%">Rosenfeld, P. J.</style></author><author><style face="normal" font="default" size="100%">Toth, C. A.</style></author><author><style face="normal" font="default" size="100%">Bernstein, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA Ophthalmology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JAMA Ophthalmology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">843-850</style></pages><volume><style face="normal" font="default" size="100%">131</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">adult // aged // aphakia // article // cataract extraction // controlled study // double blind procedure // female // follow up // human // major clinical study // male // multicenter study // priority journal // pseudophakia // randomized controlled tr</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00920190</style></accession-num><abstract><style face="normal" font="default" size="100%">Importance Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020. OBJECTIVE To determine whether daily oral supplementation with lutein/zeaxanthin affects the risk for cataract surgery. DESIGN, SETTING, AND PATIENTS The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-masked clinical trial, enrolled 4203 participants, aged 50 to 85 years, at risk for progression to advanced age-related macular degeneration. INTERVENTIONS Participants were randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated fatty acids, 1 g; or a combination to evaluate the effects on the primary outcome of progression to advanced age-related macular degeneration. MAIN OUTCOMES AND MEASURES Cataract surgerywas documented at annual study examination with the presence of pseudophakia or aphakia, or reported during telephone calls at 6-month intervals between study visits. Annual best-corrected visual acuity testing was performed. A secondary outcome of AREDS2 was to evaluate the effects of lutein/zeaxanthin on the subsequent need for cataract surgery. RESULTS A total of 3159 AREDS2 participants were phakic in at least 1 eye and 1389 of 6027 study eyes underwent cataract surgery during the study, with median follow-up of 4.7 years. The 5-year probability of progression to cataract surgery in the no lutein/zeaxanthin group was 24%. For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios for progression to cataract surgery was 0.96 (95%CI, 0.84-1.10; P = .54). For participants in the lowest quintile of dietary intake of lutein/zeaxanthin, the hazard ratio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to cataract surgery was 0.68 (95%CI, 0.48-0.96; P = .03). The hazard ratio for 3 or more lines of vision loss was 1.03 (95%CI, 0.93-1.13; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin). CONCLUSIONS AND RELEVANCE Daily supplementation with lutein/zeaxanthin had no statistically significant overall effect on rates of cataract surgery or vision loss.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/190/CN-00920190/frame.html</style></url><url><style face="normal" font="default" size="100%">http://archopht.jamanetwork.com/article.aspx?articleid=1685136</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1001/jamaophthalmol.2013.4412</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>93</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">93</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chew, E. Y.</style></author><author><style face="normal" font="default" size="100%">SanGiovanni, J. P.</style></author><author><style face="normal" font="default" size="100%">Ferris, F. L.</style></author><author><style face="normal" font="default" size="100%">Wong, W. T.</style></author><author><style face="normal" font="default" size="100%">Agron, E.</style></author><author><style face="normal" font="default" size="100%">Clemons, T. E.</style></author><author><style face="normal" font="default" size="100%">Sperduto, R.</style></author><author><style face="normal" font="default" size="100%">Danis, R.</style></author><author><style face="normal" font="default" size="100%">Chandra, S. R.</style></author><author><style face="normal" font="default" size="100%">Blodi, B. A.</style></author><author><style face="normal" font="default" size="100%">Domalpally, A.</style></author><author><style face="normal" font="default" size="100%">Elman, M. J.</style></author><author><style face="normal" font="default" size="100%">Antoszyk, A. N.</style></author><author><style face="normal" font="default" size="100%">Ruby, A. J.</style></author><author><style face="normal" font="default" size="100%">Orth, D.</style></author><author><style face="normal" font="default" size="100%">Bressler, S. B.</style></author><author><style face="normal" font="default" size="100%">Fish, G. E.</style></author><author><style face="normal" font="default" size="100%">Hubbard, G. B.</style></author><author><style face="normal" font="default" size="100%">Klein, M. L.</style></author><author><style face="normal" font="default" size="100%">Friberg, T. R.</style></author><author><style face="normal" font="default" size="100%">Rosenfeld, P. J.</style></author><author><style face="normal" font="default" size="100%">Toth, C. A.</style></author><author><style face="normal" font="default" size="100%">Bernstein, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA ophthalmology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JAMA Ophthalmology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">843-50</style></pages><volume><style face="normal" font="default" size="100%">131</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Aging</style></keyword><keyword><style face="normal" font="default" size="100%">Cataract [diagnosis] [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cataract Extraction [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acids, Omega-3 [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Lutein [blood] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Vision Disorders [diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">Visual Acuity</style></keyword><keyword><style face="normal" font="default" size="100%">Xanthophylls [blood] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00876616</style></accession-num><abstract><style face="normal" font="default" size="100%">IMPORTANCE: Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020. OBJECTIVE: To determine whether daily oral supplementation with lutein/zeaxanthin affects the risk for cataract surgery. DESIGN, SETTING, AND PATIENTS: The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-masked clinical trial, enrolled 4203 participants, aged 50 to 85 years, at risk for progression to advanced age-related macular degeneration. INTERVENTIONS: Participants were randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated fatty acids, 1 g; or a combination to evaluate the effects on the primary outcome of progression to advanced age-related macular degeneration. MAIN OUTCOMES AND MEASURES: Cataract surgery was documented at annual study examination with the presence of pseudophakia or aphakia, or reported during telephone calls at 6-month intervals between study visits. Annual best-corrected visual acuity testing was performed. A secondary outcome of AREDS2 was to evaluate the effects of lutein/zeaxanthin on the subsequent need for cataract surgery. RESULTS: A total of 3159 AREDS2 participants were phakic in at least 1 eye and 1389 of 6027 study eyes underwent cataract surgery during the study, with median follow-up of 4.7 years. The 5-year probability of progression to cataract surgery in the no lutein/zeaxanthin group was 24%. For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios for progression to cataract surgery was 0.96 (95% CI, 0.84-1.10; P = .54). For participants in the lowest quintile of dietary intake of lutein/zeaxanthin, the hazard ratio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to cataract surgery was 0.68 (95% CI, 0.48-0.96; P = .03). The hazard ratio for 3 or more lines of vision loss was 1.03 (95% CI, 0.93-1.13; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin). CONCLUSIONS AND RELEVANCE: Daily supplementation with lutein/zeaxanthin had no statistically significant overall effect on rates of cataract surgery or vision loss. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00345176.</style></abstract><work-type><style face="normal" font="default" size="100%">Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/616/CN-00876616/frame.html</style></url><url><style face="normal" font="default" size="100%">http://archopht.jamanetwork.com/article.aspx?articleid=1685136</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">Pubmed 23645227</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jamaophthalmol.2013.4412</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>128</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">128</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choi, Kee-Hong</style></author><author><style face="normal" font="default" size="100%">Wykes, Til</style></author><author><style face="normal" font="default" size="100%">Kurtz, Matthew M.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Akhondzadeh, Amminger Buchanan Buchanan De Gracia Dominguez Dickinson Dyer Fagerlund Freudenreich Friedman Gladsjo Glass Glass Gleser Goff Goff Goff Goff Goff Goff Green Green Green Green Harvey Harvey Hawkins Hedges Hedges Hedges Javitt Keefe Keefe Keefe Keefe Keefe Kohler Kohler Lane Lee Lee Lindenmayer Lipsey McGurk Moher Nuechterlein Nuechterlein Orwin Pikuli Poyurovsky Rosenthal Saykin Schubert Schubert Sharma Shiina Sumiyoshi Sumiyoshi Sumiyoshi Tsai Tsai Tsai Tsai Wykes Wykes</style></author></secondary-authors></contributors><auth-address><style face="normal" font="default" size="100%">Kurtz, Matthew M.: Department of Psychology, Wesleyan University, Judd Hall, 207 High Street, Middletown, CT, US, 06459, mkurtz@wesleyan.edu&#xD;Kurtz, Matthew M.: mkurtz@wesleyan.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: Meta-analytical investigation of efficacy</style></title><tertiary-title><style face="normal" font="default" size="100%">Journal of Mental Science</style></tertiary-title></titles><pages><style face="normal" font="default" size="100%">172-178</style></pages><volume><style face="normal" font="default" size="100%">203</style></volume><number><style face="normal" font="default" size="100%">Clinical Psychopharmacology [3340]</style></number><edition><style face="normal" font="default" size="100%">3</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Drug Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Schizophrenia</style></keyword><keyword><style face="normal" font="default" size="100%">*Treatment Effectiveness Evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">*Adjunctive Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Cognitive Impairment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">United Kingdom</style></pub-location><publisher><style face="normal" font="default" size="100%">Royal College of Psychiatrists&#xD;United Kingdom</style></publisher><isbn><style face="normal" font="default" size="100%">0007-1250</style></isbn><abstract><style face="normal" font="default" size="100%">Background: A growing number of studies have investigated the efficacy of novel, adjunctive pharmacotherapies for treatment of cognitive deficits in schizophrenia with conflicting results. Aims: To investigate the comparative efficacy of these agents on cognition and symptoms in schizophrenia, and to identify promising cognitive domains and candidate medications that can be incorporated in treatment trials combined with cognitive remediation to maximise treatment effects. Method: A total of 26 double-blind, placebo-controlled studies investigating medications targeted at cholinergic, glutamatergic or serotonergic receptor classes and with participants with schizophrenia or schizoaffective disorder were identified. Results: Medications targeted at the cholinergic receptor class produced marginal improvements in verbal learning and memory (d = 0.23, P = 0.06), and donepezil, a specific type of cholinergic agonist, produced a moderate effect (d = 0.58) on spatial learning and memory. Cholinergic and glutamatergic agents produced moderate effect-size improvements on negative symptoms (d = 0.54 and d = 0.62 respectively), and small effect-size improvements on general symptoms (d = 0.46 and d = 0.41 respectively). Serotonergic agents produced small effect-size improvements in positive symptoms (d = 0.33). Conclusions: Cholinergic medications produced marginal improvement in verbal learning and memory and moderate improvements on spatial learning and memory, although there was no evidence to support the use of glutamatergic or serotonergic medications as a stand-alone treatment for improving cognitive function. Cholinergic and glutamatergic agents improved negative and general symptoms, whereas serotenergic medications improved positive symptoms. (PsycINFO Database Record (c) 2013 APA, all rights reserved) (journal abstract)</style></abstract><notes><style face="normal" font="default" size="100%">The British Journal of Psychiatry</style></notes><work-type><style face="normal" font="default" size="100%">Schizophrenia &amp; Psychotic States 3213</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=psyc8&amp;NEWS=N&amp;AN=2013-32050-006</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>118</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">118</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choi, K. H.</style></author><author><style face="normal" font="default" size="100%">Til, W.</style></author><author><style face="normal" font="default" size="100%">Kurtz, M. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.M. Kurtz, Department of Psychology, Wesleyan University, Judd Hall, 207 High Street, Middletown, CT 06459, United States. E-mail: mkurtz@wesleyan.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: Meta-analytical investigation of efficacy</style></title></titles><pages><style face="normal" font="default" size="100%">172-178</style></pages><volume><style face="normal" font="default" size="100%">203</style></volume><number><style face="normal" font="default" size="100%">(Choi) Department of Psychology, Korea University, Seoul, South Korea</style></number><edition><style face="normal" font="default" size="100%">3</style></edition><keywords><keyword><style face="normal" font="default" size="100%">clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">*cognitive defect/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">learning</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">negative syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">positive syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">*psychopharmacotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">*schizophrenia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">spatial learning</style></keyword><keyword><style face="normal" font="default" size="100%">spatial memory</style></keyword><keyword><style face="normal" font="default" size="100%">verbal memory</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">glutamate receptor agonist/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin 1A agonist/dt [Drug Therapy]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">United Kingdom</style></pub-location><publisher><style face="normal" font="default" size="100%">Royal College of Psychiatrists (17 Belgrave Square, London SW1X 8PG, United Kingdom)</style></publisher><isbn><style face="normal" font="default" size="100%">0007-1250</style></isbn><abstract><style face="normal" font="default" size="100%">Background: A growing number of studies have investigated the efficacy of novel, adjunctive pharmacotherapies for treatment of cognitive deficits in schizophrenia with conflicting results. Aims: To investigate the comparative efficacy of these agents on cognition and symptoms in schizophrenia, and to identify promising cognitive domains and candidate medications that can be incorporated in treatment trials combined with cognitive remediation to maximise treatment effects. Method: A total of 26 double-blind, placebo-controlled studies investigating medications targeted at cholinergic, glutamatergic or serotonergic receptor classes and with participants with schizophrenia or schizoaffective disorder were identified. Results: Medications targeted at the cholinergic receptor class produced marginal improvements in verbal learning and memory (d = 0.23, P = 0.06), and donepezil, a specific type of cholinergic agonist, produced a moderate effect (d = 0.58) on spatial learning and memory. Cholinergic and glutamatergic agents produced moderate effect-size improvements on negative symptoms (d = 0.54 and d = 0.62 respectively), and small effect-size improvements on general symptoms (d = 0.46 and d = 0.41 respectively). Serotonergic agents produced small effect-size improvements in positive symptoms (d = 0.33). Conclusions: Cholinergic medications produced marginal improvement in verbal learning and memory and moderate improvements on spatial learning and memory, although there was no evidence to support the use of glutamatergic or serotonergic medications as a stand-alone treatment for improving cognitive function. Cholinergic and glutamatergic agents improved negative and general symptoms, whereas serotenergic medications improved positive symptoms.</style></abstract><notes><style face="normal" font="default" size="100%">British Journal of Psychiatry</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://bjp.rcpsych.org/content/203/3/172.full.pdf+html</style></url><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013557835</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>105</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">105</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cook, C.</style></author><author><style face="normal" font="default" size="100%">Learman, K.</style></author><author><style face="normal" font="default" size="100%">Showalter, C.</style></author><author><style face="normal" font="default" size="100%">Kabbaz, V.</style></author><author><style face="normal" font="default" size="100%">O&apos;Halloran, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Early use of thrust manipulation versus non-thrust manipulation: A randomized clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">Manual Therapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Manual Therapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">191-198</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">adult // article // controlled study // equipoise // exercise // female // follow up // home care // hospital discharge // hospitalization // human // intermethod comparison // low back pain/th [Therapy] // major clinical study // male // manipulative m</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00907133</style></accession-num><abstract><style face="normal" font="default" size="100%">The purpose of this study was to investigate the comparative effectiveness of early use of thrust (TM) and non-thrust manipulation (NTM) in sample of patients with mechanical low back pain (LBP). The randomized controlled trial included patients with mechanically reproducible LBP, &gt;=age 18-years who were randomized into two treatment groups. The main outcome measures were the Oswestry Disability Index (ODI) and a Numeric Pain Rating Scale (NPRS), with secondary measures of Rate of Recovery, total visits and days in care, and the work subscale of the Fears Avoidance Beliefs Questionnaire work subscale (FABQ-w). A two-way mixed model MANCOVA was used to compare ODI and pain, at baseline, after visit 2, and at discharge and total visits, days in care, and rate of recovery (while controlling for patient expectations and clinical equipoise). A total of 149 subjects completed the trial and received care over an average of 35 days. There were no significant differences between TM and NTM at the second visit follow-up or at discharge with any of the outcomes categories. Personal equipoise was significantly associated with ODI and pain. The findings suggest that there is no difference between early use of TM or NTM, and secondarily, that personal equipoise affects study outcome. Within-groups changes were significant for both groups. 2012 Elsevier Ltd.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/133/CN-00907133/frame.html</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.math.2012.08.005</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>103</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">103</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cook, C. E.</style></author><author><style face="normal" font="default" size="100%">Learman, K. E.</style></author><author><style face="normal" font="default" size="100%">O&apos;Halloran, B. J.</style></author><author><style face="normal" font="default" size="100%">Showalter, C. R.</style></author><author><style face="normal" font="default" size="100%">Kabbaz, V. J.</style></author><author><style face="normal" font="default" size="100%">Goode, A. P.</style></author><author><style face="normal" font="default" size="100%">Wright, A. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Which prognostic factors for low back pain are generic predictors of outcome across a range of recovery domains?</style></title><secondary-title><style face="normal" font="default" size="100%">Physical therapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Physical therapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">32-40</style></pages><volume><style face="normal" font="default" size="100%">93</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">adolescent // adult // aged // article // controlled clinical trial // controlled study // decision support system // disability // female // human // low back pain/th [Therapy] // male // middle aged // pathophysiology // physiotherapy // Poisson distr</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00911865</style></accession-num><abstract><style face="normal" font="default" size="100%">Recovery from low back pain (LBP) is multidimensional and requires the use of multiple-response (outcome) measures to fully reflect these many dimensions. Predictive prognostic variables that are present or stable in all or most predictive models that use different outcome measures could be considered &quot;universal&quot; prognostic variables. The aim of this study was to explore the potential of universal prognostic variables in predictive models for 4 different outcome measures in patients with mechanical LBP. Predictive modeling was performed using data extracted from a randomized controlled trial. Four prognostic models were created using backward stepwise deletion logistic, Poisson, and linear regression. Data were collected from 16 outpatient physical therapy facilities in 10 states. All 149 patients with LBP were treated with manual therapy and spine strengthening exercises until discharge. Four different measures of response were used: Oswestry Disability Index and Numeric Pain Rating Scale change scores, total visits, and report of rate of recovery. The set of statistically significant predictors was dependent on the definition of response. All regression models were significant. Within both forms of the 4 models, meeting the clinical prediction rule for manipulation at baseline was present in all 4 models, whereas no irritability at baseline and diagnosis of sprains and strains were present in 2 of 4 of the predictive models. The primary limitation is that this study evaluated only 4 of the multiple outcome measures that are pertinent for patients with LBP. Meeting the clinical prediction rule was prognostic for all outcome measures and should be considered a universal prognostic predictor. Other predictive variables were dependent on the outcomes measure used in the predictive model.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/865/CN-00911865/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ptjournal.apta.org/content/93/1/32.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1374344043/Cook-2013-Which prognostic fac.pdf</url></pdf-urls></urls><custom3><style face="normal" font="default" size="100%">Pubmed 22879443</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.2522/ptj.20120216</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>87</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">87</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cummings Jeffrey, L.</style></author><author><style face="normal" font="default" size="100%">Geldmacher, David</style></author><author><style face="normal" font="default" size="100%">Farlow, Martin</style></author><author><style face="normal" font="default" size="100%">Sabbagh, Marwan</style></author><author><style face="normal" font="default" size="100%">Christensen, Daniel</style></author><author><style face="normal" font="default" size="100%">Betz, Peter</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer&apos;s Disease: Drug Profile and Clinical Guidelines</style></title><secondary-title><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">CNS neuroscience &amp; therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">294-301</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Sr-dementia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">Cn-00863216</style></accession-num><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/216/CN-00863216/frame.html</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>94</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">94</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Deneux-Tharaux, C.</style></author><author><style face="normal" font="default" size="100%">Sentilhes, L.</style></author><author><style face="normal" font="default" size="100%">Maillard, F.</style></author><author><style face="normal" font="default" size="100%">Closset, E.</style></author><author><style face="normal" font="default" size="100%">Vardon, D.</style></author><author><style face="normal" font="default" size="100%">Lepercq, J.</style></author><author><style face="normal" font="default" size="100%">Goffinet, F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of routine controlled cord traction as part of the active management of the third stage of labour on postpartum haemorrhage: multicentre randomised controlled trial (TRACOR)</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ (Clinical research ed.)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ (Clinical research ed.)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">f1541</style></pages><volume><style face="normal" font="default" size="100%">346</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">France</style></keyword><keyword><style face="normal" font="default" size="100%">Labor Stage, Third</style></keyword><keyword><style face="normal" font="default" size="100%">Labor, Obstetric</style></keyword><keyword><style face="normal" font="default" size="100%">Placenta</style></keyword><keyword><style face="normal" font="default" size="100%">Postpartum Hemorrhage [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Umbilical Cord</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">Cn-00862011</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To assess the impact of controlled cord traction on the incidence of postpartum haemorrhage and other characteristics of the third stage of labour in a high resource setting. DESIGN: Randomised controlled trial. SETTING: Five university hospital maternity units in France. PARTICIPANTS: Women aged 18 or more with a singleton fetus at 35 or more weeks&apos; gestation and planned vaginal delivery. INTERVENTIONS: Women were randomly assigned to management of the third stage of labour by controlled cord traction or standard placenta expulsion (awaiting spontaneous placental separation before facilitating expulsion). Women in both arms received prophylactic oxytocin just after birth. MAIN OUTCOME MEASURE: Incidence of postpartum haemorrhage ≥ 500 mL as measured in a collector bag. RESULTS: The incidence of postpartum haemorrhage did not differ between the controlled cord traction arm (9.8%, 196/2005) and standard placenta expulsion arm (10.3%, 206/2008): relative risk 0.95 (95% confidence interval 0.79 to 1.15). The need for manual removal of the placenta was significantly less frequent in the controlled cord traction arm (4.2%, 85/2033) compared with the standard placenta expulsion arm (6.1%, 123/2024): relative risk 0.69, 0.53 to 0.90); as was third stage of labour of more than 15 minutes (4.5%, 91/2030 and 14.3%, 289/2020, respectively): relative risk 0.31, 0.25 to 0.39. Women in the controlled cord traction arm reported a significantly lower intensity of pain and discomfort during the third stage than those in the standard placenta expulsion arm. No uterine inversion occurred in either arm. CONCLUSIONS: In a high resource setting, the use of controlled cord traction for the management of placenta expulsion had no significant effect on the incidence of postpartum haemorrhage and other markers of postpartum blood loss. Evidence to recommend routine controlled cord traction for the management of placenta expulsion to prevent postpartum haemorrhage is therefore lacking. TRIAL REGISTRATION: ClinicalTrials.gov NCT01044082.</style></abstract><work-type><style face="normal" font="default" size="100%">Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov&apos;t</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/011/CN-00862011/frame.html</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">Pubmed 23538918</style></custom3></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>89</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">89</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Doyle, O. M.</style></author><author><style face="normal" font="default" size="100%">Ashburner, J.</style></author><author><style face="normal" font="default" size="100%">Zelaya, F. O.</style></author><author><style face="normal" font="default" size="100%">Williams, S. C. R.</style></author><author><style face="normal" font="default" size="100%">Mehta, M. A.</style></author><author><style face="normal" font="default" size="100%">Marquand, A. F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Multivariate decoding of brain images using ordinal regression</style></title><secondary-title><style face="normal" font="default" size="100%">NeuroImage</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">NeuroImage</style></full-title></periodical><pages><style face="normal" font="default" size="100%">347-357</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><keywords><keyword><style face="normal" font="default" size="100%">accuracy // adult // analytical error // article // brain blood flow // brain radiography // classification // controlled study // crossover procedure // double blind procedure // electroencephalogram // human // human experiment // intermethod comparis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00905699</style></accession-num><abstract><style face="normal" font="default" size="100%">Neuroimaging data are increasingly being used to predict potential outcomes or groupings, such as clinical severity, drug dose response, and transitional illness states. In these examples, the variable (target) we want to predict is ordinal in nature. Conventional classification schemes assume that the targets are nominal and hence ignore their ranked nature, whereas parametric and/or non-parametric regression models enforce a metric notion of distance between classes. Here, we propose a novel, alternative multivariate approach that overcomes these limitations - whole brain probabilistic ordinal regression using a Gaussian process framework. We applied this technique to two data sets of pharmacological neuroimaging data from healthy volunteers. The first study was designed to investigate the effect of ketamine on brain activity and its subsequent modulation with two compounds - lamotrigine and risperidone. The second study investigates the effect of scopolamine on cerebral blood flow and its modulation using donepezil. We compared ordinal regression to multi-class classification schemes and metric regression. Considering the modulation of ketamine with lamotrigine, we found that ordinal regression significantly outperformed multi-class classification and metric regression in terms of accuracy and mean absolute error. However, for risperidone ordinal regression significantly outperformed metric regression but performed similarly to multi-class classification both in terms of accuracy and mean absolute error. For the scopolamine data set, ordinal regression was found to outperform both multi-class and metric regression techniques considering the regional cerebral blood flow in the anterior cingulate cortex. Ordinal regression was thus the only method that performed well in all cases. Our results indicate the potential of an ordinal regression approach for neuroimaging data while providing a fully probabilistic framework with elegant approaches for model selection. 2013.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/699/CN-00905699/frame.html</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.neuroimage.2013.05.036</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>71</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">71</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ferris, S.</style></author><author><style face="normal" font="default" size="100%">Cummings, J.</style></author><author><style face="normal" font="default" size="100%">Christensen, D.</style></author><author><style face="normal" font="default" size="100%">Doody, R.</style></author><author><style face="normal" font="default" size="100%">Farlow, M.</style></author><author><style face="normal" font="default" size="100%">Sabbagh, M.</style></author><author><style face="normal" font="default" size="100%">Liu, L.</style></author><author><style face="normal" font="default" size="100%">MacKell, J.</style></author><author><style face="normal" font="default" size="100%">Fain, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer&apos;s disease: Evaluating the impact of baseline severity</style></title><secondary-title><style face="normal" font="default" size="100%">Alzheimer&apos;s Research and Therapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Alzheimer&apos;s Research and Therapy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">aged // Alzheimer disease/dt [Drug Therapy] // article // attention // cognition // cohort analysis // controlled study // depth perception // descriptive research // disease severity // double blind procedure // drug dose comparison // female // human</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00908032</style></accession-num><abstract><style face="normal" font="default" size="100%">Introduction. The US Food and Drug Administration approved a 23 mg daily dose of donepezil for treatment of moderate to severe Alzheimer&apos;s disease (AD) based on outcomes from a large trial comparing the 23 mg/day dose with the standard 10 mg/day dose. Results from this study indicated that after 24 weeks, donepezil 23 mg/day provided significant cognitive benefits over donepezil 10 mg/day, measured using the Severe Impairment Battery (SIB). In the analyses reported herein, we further characterize the range of cognitive domains impacted by treatment with donepezil 23 mg/day. Methods. A post hoc analysis was conducted using data from a 24-week, randomized, double-blind trial comparing donepezil 23 mg/day versus 10 mg/day in 1,467 patients with moderate to severe AD (baseline Mini-Mental State Examination (MMSE) score 0 to 20). Changes from baseline to week 24 in the nine SIB domain scores were analyzed in the intent-to-treat (ITT) population (baseline MMSE 0 to 20), in patients with more severe baseline AD (MMSE 0 to 16), and in severity strata based on baseline MMSE scores (0 to 5, 6 to 10, 11 to 15, 16 to 20). Results: In the ITT population, changes in six of the nine SIB domains favored donepezil 23 mg/day over donepezil 10 mg/day. LS mean treatment differences were significant for the language, visuospatial ability, and construction domains. In the more advanced cohort of patients (MMSE 0 to 16 at baseline), LS mean treatment differences were statistically significant favoring donepezil 23 mg/day in five of the nine domains: language, memory, visuospatial ability, attention, and construction. Descriptive analysis of LS mean changes in SIB domain scores in the four baseline severity strata showed variable patterns of response; overall, cognitive benefits of donepezil 23 mg/day were greatest in patients with MMSE scores of 0 to 15. Conclusions: These results suggest that donepezil 23 mg/day provides benefits over 10 mg/day across a range of cognitive domains. The magnitude of benefit and domains impacted varied depending on the stage of AD; significant benefits with higher dose donepezil were most apparent at more advanced stages of AD and were most prominent in the language domain. 2013 Ferris et al.; licensee BioMed Central Ltd.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/032/CN-00908032/frame.html</style></url><url><style face="normal" font="default" size="100%">http://alzres.com/content/pdf/alzrt166.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0628175011/Ferris-2013-Effects of donepezil.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/alzrt166</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>125</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">125</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Froestl, W.</style></author><author><style face="normal" font="default" size="100%">Muhs, A.</style></author><author><style face="normal" font="default" size="100%">Pfeifer, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">W. Froestl, AC Immune SA, EPFL Quartier de I&apos;innovation Building B, CH-1015 Lausanne, Switzerland. E-mail: wolfgang.froestl@acimmune.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cognitive enhancers (nootropics). Part 2: Drugs interacting with enzymes</style></title></titles><pages><style face="normal" font="default" size="100%">547-658</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">(Froestl, Muhs, Pfeifer) AC Immune SA, EPFL Quartier de I&apos;innovation Building B, CH-1015 Lausanne, Switzerland</style></number><edition><style face="normal" font="default" size="100%">3</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">dementia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Down syndrome/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">drug bioavailability</style></keyword><keyword><style face="normal" font="default" size="100%">drug cost</style></keyword><keyword><style face="normal" font="default" size="100%">drug delivery device</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug formulation</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug structure</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">IC 50</style></keyword><keyword><style face="normal" font="default" size="100%">liver toxicity/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">low drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">memory disorder/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">mild cognitive impairment/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">multiple sclerosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">ads 8704</style></keyword><keyword><style face="normal" font="default" size="100%">amr 109/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">arimenda</style></keyword><keyword><style face="normal" font="default" size="100%">bisnorcymserine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor/cr [Drug Concentration]</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor/dv [Drug Development]</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor/pk [Pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">coumarin derivative/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/po [Oral Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/pr [Pharmaceutics]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/pk [Pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/td [Transdermal Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil plus memantine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">eht 0202</style></keyword><keyword><style face="normal" font="default" size="100%">etazolate/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">etazolate/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">etazolate/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/cr [Drug Concentration]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/pk [Pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">gln 1062</style></keyword><keyword><style face="normal" font="default" size="100%">huperzine A/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">huperzine A/cr [Drug Concentration]</style></keyword><keyword><style face="normal" font="default" size="100%">huperzine A/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">huperzine A/po [Oral Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">huperzine A/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">idn 5706/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">inm 176</style></keyword><keyword><style face="normal" font="default" size="100%">iqm 622/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">kr wap 026</style></keyword><keyword><style face="normal" font="default" size="100%">ladostigil/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">ladostigil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">ladostigil/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">lipocrine/cr [Drug Concentration]</style></keyword><keyword><style face="normal" font="default" size="100%">lipocrine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">memogain/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">memogain/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">memogain/na [Intranasal Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">memoquin/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">methanesulfonyl fluoride/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">methanesulfonyl fluoride/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">methanesulfonyl fluoride/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">mhp 133/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">miq 001/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">miq 001/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*nootropic agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">np 0361</style></keyword><keyword><style face="normal" font="default" size="100%">np 61/cr [Drug Concentration]</style></keyword><keyword><style face="normal" font="default" size="100%">np 61/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">omega 3 fatty acid/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">phenserine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">phenserine/po [Oral Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">phenserine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">prodrug/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">prodrug/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">prodrug/na [Intranasal Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">protein inhibitor/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine/td [Transdermal Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">ro 46 5934/dv [Drug Development]</style></keyword><keyword><style face="normal" font="default" size="100%">tacrine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">tacrine/cr [Drug Concentration]</style></keyword><keyword><style face="normal" font="default" size="100%">tacrine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">tacrine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">unindexed drug</style></keyword><keyword><style face="normal" font="default" size="100%">win 026/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">win 026/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">win 026/pk [Pharmacokinetics]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">Netherlands</style></pub-location><publisher><style face="normal" font="default" size="100%">IOS Press (Nieuwe Hemweg 6B, Amsterdam 1013 BG, Netherlands)</style></publisher><isbn><style face="normal" font="default" size="100%">1387-2877</style></isbn><abstract><style face="normal" font="default" size="100%">Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer&apos;s disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, applying knowledge, and changing preferences. It involves memory, attention, executive functions, perception, language, and psychomotor functions. The term nootropics was coined in 1972 when memory enhancing properties of piracetam were observed in clinical trials. In the meantime, hundreds of drugs have been evaluated in clinical trials or in preclinical experiments. To classify the compounds, a concept is proposed assigning drugs to 19 categories according to their mechanism(s) of action, in particular drugs interacting with receptors, enzymes, ion channels, nerve growth factors, re-uptake transporters, antioxidants, metal chelators, and disease modifying drugs meaning small molecules, vaccines, and monoclonal antibodies interacting with amyloid-beta and tau. For drugs whose mechanism of action is not known, they are either classified according to structure, e.g., peptides, or their origin, e.g., natural products. This review covers the evolution of research in this field over the last 25 years. 2013 - IOS Press and the authors. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Journal of Alzheimer&apos;s Disease</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013053284</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>68</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">68</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gadiko, C.</style></author><author><style face="normal" font="default" size="100%">Koundinya Tippabhotla, S.</style></author><author><style face="normal" font="default" size="100%">Thota, S.</style></author><author><style face="normal" font="default" size="100%">Battula, R.</style></author><author><style face="normal" font="default" size="100%">Khan, M. S.</style></author><author><style face="normal" font="default" size="100%">Vobalaboina, V.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A randomized, crossover, single-dose bioequivalence study of two extended-release tablets of donepezil 23 mg in healthy human volunteers under fasting and fed states</style></title><secondary-title><style face="normal" font="default" size="100%">Scientia Pharmaceutica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Scientia Pharmaceutica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">777-791</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">adult // anisocoria/si [Side Effect] // area under the curve // article // asthenia/si [Side Effect] // backache/si [Side Effect] // bioequivalence // blood sampling // crossover procedure // diet restriction // dietary intake // drug bioavailability //</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00914335</style></accession-num><abstract><style face="normal" font="default" size="100%">To assess the bioequivalence of two extended-release tablets of donepezil 23 mg, open label, randomized, single-dose, two-sequence, two-period cross-over studies under fasting (n=74) and fed (n=94) conditions in healthy adult human volunteers were conducted. Subjects were randomized to either of the two treatment arms (test or reference) separated by a washout period of 28 days. Blood samples were collected up to 72 h post-dose and plasma samples were analyzed for donepezil using a validated LC-MS/MS method. Pharmaco-kinetic parameters were derived using a non-compartmental approach. Bioequivalence was evaluated in 69 subjects in the fasting study, and 71 subjects in the fed study. In the fasting study, the 90% CI of Cmax and AUC0-72 were 82.50-90.10 and 92.38-98.60, respectively. Corresponding values in the fed study were 91.82-98.05 and 97.27-100.27. Based on the results, the test product (donepezil) met the US regulatory criteria of bioequivalence relative to the reference product (Aricept) under both fasting and fed conditions. Gadiko et al.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/335/CN-00914335/frame.html</style></url><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791939/pdf/scipharm_2013_81_777.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2426206510/Gadiko-2013-A randomized, crosso.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.3797/scipharm.1302-13</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>97</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">97</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grasing, K.</style></author><author><style face="normal" font="default" size="100%">Mathur, D.</style></author><author><style face="normal" font="default" size="100%">Newton, T. F.</style></author><author><style face="normal" font="default" size="100%">DeSouza, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Individual predictors of the subjective effects of intravenous cocaine</style></title><secondary-title><style face="normal" font="default" size="100%">Psychiatry Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Psychiatry Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">245-251</style></pages><volume><style face="normal" font="default" size="100%">208</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Addiction Severity Index // adult // article // cocaine dependence/dt [Drug Therapy] // controlled clinical trial // controlled study // disease association // disease severity // double blind procedure // drug abuse pattern // euphoria // family confli</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00914375</style></accession-num><abstract><style face="normal" font="default" size="100%">The subjective and reinforcing effects of addictive substances can vary greatly between individuals. This study compared the relative contributions of baseline drug use, craving, stressful life events, and social factors in determining the subjective effects of cocaine in individual participants. Twelve veterans meeting criteria for cocaine dependence were evaluated in a laboratory setting. Self-report of the subjective effects of intravenous cocaine was recorded following single- and double-blind, placebo-controlled injections. Increased positive subjective effects of cocaine, including drug-induced &apos;good&apos; effects and the value of intravenous injections, were most strongly correlated with greater family and social dysfunction measured through the Addiction Severity Index (ASI). Social dysfunction was the strongest predictor of cocaine-induced euphoria, accounting for approximately one-half of its variability. Participants who were dissatisfied with their current marital status reported almost no &apos;bad&apos; effects of cocaine but instead reported increased drug-induced &apos;high&apos;, euphoria, and injection value. Although further research is required to determine the generalizability of this association, our findings are parallel to recent preclinical results showing that social interaction can attenuate psychostimulant reward. Effects of substance abuse treatment that rely on improved social function may be mediated through changes in the brain&apos;s reinforcement system that modify the rewarding effects of cocaine. 2013.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/375/CN-00914375/frame.html</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.psychres.2013.05.028</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>82</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">82</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hashimoto, Kenji</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Potential role of the sigma-1 receptor chaperone in the beneficial effects of donepezil in dementia with Lewy bodies</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical psychopharmacology &amp; neuroscience</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical psychopharmacology &amp; neuroscience</style></full-title></periodical><pages><style face="normal" font="default" size="100%">43-4</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Sr-dementia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">Cn-00872968</style></accession-num><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/968/CN-00872968/frame.html</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>109</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">109</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ikeda, K.</style></author><author><style face="normal" font="default" size="100%">Hagino, Y.</style></author><author><style face="normal" font="default" size="100%">Kasai, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K. Ikeda, Addictive Substance Project, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dopamine-independent motor control and hyperactivity involving acetylcholine systems</style></title><tertiary-title><style face="normal" font="default" size="100%">52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP 2013 Hollywood, FL United States. Conference Start: 20131208 Conference End: 20131212&#xD;(var.pagings)</style></tertiary-title></titles><pages><style face="normal" font="default" size="100%">S277-S278</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">(Ikeda, Hagino, Kasai) Addictive Substance Project, Tokyo, Japan</style></number><keywords><keyword><style face="normal" font="default" size="100%">*motor control</style></keyword><keyword><style face="normal" font="default" size="100%">*hyperactivity</style></keyword><keyword><style face="normal" font="default" size="100%">*psychopharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*college</style></keyword><keyword><style face="normal" font="default" size="100%">dopamine deficient mouse</style></keyword><keyword><style face="normal" font="default" size="100%">Japan</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia</style></keyword><keyword><style face="normal" font="default" size="100%">mouse</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">basal ganglion</style></keyword><keyword><style face="normal" font="default" size="100%">corpus striatum</style></keyword><keyword><style face="normal" font="default" size="100%">motor dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">animal experiment</style></keyword><keyword><style face="normal" font="default" size="100%">locomotion</style></keyword><keyword><style face="normal" font="default" size="100%">gene</style></keyword><keyword><style face="normal" font="default" size="100%">high performance liquid chromatography</style></keyword><keyword><style face="normal" font="default" size="100%">electrochemical detection</style></keyword><keyword><style face="normal" font="default" size="100%">housing</style></keyword><keyword><style face="normal" font="default" size="100%">animal care</style></keyword><keyword><style face="normal" font="default" size="100%">positive syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">knockout mouse</style></keyword><keyword><style face="normal" font="default" size="100%">lethality</style></keyword><keyword><style face="normal" font="default" size="100%">procedures</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">synthesis</style></keyword><keyword><style face="normal" font="default" size="100%">modulation</style></keyword><keyword><style face="normal" font="default" size="100%">cholinergic nerve cell</style></keyword><keyword><style face="normal" font="default" size="100%">cholinergic system</style></keyword><keyword><style face="normal" font="default" size="100%">brain</style></keyword><keyword><style face="normal" font="default" size="100%">sensor</style></keyword><keyword><style face="normal" font="default" size="100%">precursor</style></keyword><keyword><style face="normal" font="default" size="100%">immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">promoter region</style></keyword><keyword><style face="normal" font="default" size="100%">immunoblotting</style></keyword><keyword><style face="normal" font="default" size="100%">feeding</style></keyword><keyword><style face="normal" font="default" size="100%">metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">hindlimb</style></keyword><keyword><style face="normal" font="default" size="100%">agonist</style></keyword><keyword><style face="normal" font="default" size="100%">computer program</style></keyword><keyword><style face="normal" font="default" size="100%">image analysis</style></keyword><keyword><style face="normal" font="default" size="100%">protein expression</style></keyword><keyword><style face="normal" font="default" size="100%">walking</style></keyword><keyword><style face="normal" font="default" size="100%">medicine</style></keyword><keyword><style face="normal" font="default" size="100%">pedunculopontine tegmental nucleus</style></keyword><keyword><style face="normal" font="default" size="100%">gait</style></keyword><keyword><style face="normal" font="default" size="100%">camera</style></keyword><keyword><style face="normal" font="default" size="100%">synaptic transmission</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">pathophysiology</style></keyword><keyword><style face="normal" font="default" size="100%">model</style></keyword><keyword><style face="normal" font="default" size="100%">velocity</style></keyword><keyword><style face="normal" font="default" size="100%">habituation</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson disease</style></keyword><keyword><style face="normal" font="default" size="100%">professional standard</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">dopaminergic system</style></keyword><keyword><style face="normal" font="default" size="100%">*acetylcholine</style></keyword><keyword><style face="normal" font="default" size="100%">*dopamine</style></keyword><keyword><style face="normal" font="default" size="100%">*clozapine</style></keyword><keyword><style face="normal" font="default" size="100%">*atypical antipsychotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">cholinergic receptor stimulating agent</style></keyword><keyword><style face="normal" font="default" size="100%">levodopa</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin</style></keyword><keyword><style face="normal" font="default" size="100%">choline acetyltransferase</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil</style></keyword><keyword><style face="normal" font="default" size="100%">muscarinic agent</style></keyword><keyword><style face="normal" font="default" size="100%">adrenalin</style></keyword><keyword><style face="normal" font="default" size="100%">oxotremorine M</style></keyword><keyword><style face="normal" font="default" size="100%">cholinergic receptor</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol</style></keyword><keyword><style face="normal" font="default" size="100%">noradrenalin</style></keyword><keyword><style face="normal" font="default" size="100%">oxygenase</style></keyword><keyword><style face="normal" font="default" size="100%">marker</style></keyword><keyword><style face="normal" font="default" size="100%">esterase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">tyrosine 3 monooxygenase</style></keyword><keyword><style face="normal" font="default" size="100%">DOPA</style></keyword><keyword><style face="normal" font="default" size="100%">muscarinic receptor blocking agent</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">Nature Publishing Group</style></publisher><isbn><style face="normal" font="default" size="100%">0893-133X</style></isbn><abstract><style face="normal" font="default" size="100%">Background: The disruption of dopamine (DA) systems has been implicated in major neurological and psychiatric disorders, including Parkinson&apos;s disease (PD) and schizophrenia. However, effective movement in patients with Parkinson&apos;s disease in certain situations, kinesia paradoxa, and typical antipsychotic-resistant and atypical antipsychotic- sensitive positive symptoms of schizophrenia and their underlying mechanisms remain to be elucidated. Methods: The experimental procedures and housing conditions were approved by the Institutional Animal Care and Use Committee (Animal Experimentation Ethics Committee of Tokyo Metropolitan Institute of Medical Science, Approval ID: 12-43), and all of the animals were cared for and treated humanely in accordance with our institutional animal experimentation guidelines. Dopamine-deficient (DD) mice were generated using a transgenic rescue approach, in which tyrosine hydroxylase (TH) expression in noradrenergic and adrenergic cells in mice that lack TH expression was complemented by a specific DA b-hydroxylase gene promoter. These mice exhibited a restoration of norepinephrine (NE) and epinephrine synthesis and prevention of the usual perinatal lethality and cardiac dysfunction observed in TH knockout mice. Dopamine, serotonin, NE, and acetylcholine (ACh) concentrations in brain microdialysates were determined by high-performance liquid chromatography with electrochemical detection (HTEC-500, Eicom, Kyoto, Japan). Locomotor activity was measured with Supermex (Muromachi Kikai, Tokyo, Japan) and a sensor monitor mounted above the chamber. After a 180 min habituation period, the drugs were administered subcutaneously, and locomotor activity was monitored continuously for 180 min. The mice walked freely on the runway, and their locomotor movements were recorded at 200 frames per second using a high-speed digital image camera system (HAS-220, DITECT, Tokyo, Japan). Movement analyses were limited to the sagittal plane parallel to the direction of walking. Custom-designed image analysis software (DIPP-Motion 2D, DITECT, Tokyo, Japan) was used to extract the two-dimensional coordinates of the various joint markers and reconstruct a stick diagram representation of the right hindlimb. The expression profiles of the genes related to ACh metabolism and signaling transduction pathways were analyzed using the Illumina iScan system with MouseRef-8 Expression Bead- Chips (Illumina, San Diego, CA, USA), which contain probes that detect over 24 000 transcripts. Immunoblot analysis and immunohistochemistry were also performed. Results: The present study showed that DD mice can move effectively and are rather hyperactive. DD mice require daily administration of L-dihydroxyphenylalanine (L-DOPA), the precursor of DA, to maintain feeding. After 3 days withdrawal from L-DOPA, their striatal extracellular DA levels fell to less than 0.2% of wildtype mice, and they were hyperactive with a slight movement disorder in a novel environment. The atypical antipsychotic drug clozapine markedly ameliorated this hyperactivity, with no effect of the typical antipsychotic drug haloperidol. Furthermore, the nonselective muscarinic ACh receptor agonist oxotremorine- M and ACh esterase inhibitor donepezil blocked hyperactivity in DD mice. These mice exhibited a reduction of choline acetyltransferase (ChAT) gene and protein expression in the basal ganglia and a reduction of extracellular ACh levels in the striatum, suggesting that reduced cholinergic function may underlie hyperactivity in DD mice. Conclusions: The DD mice in the present study revealed a novel motor-control and hyperactivity mechanism that is independent of DA and involves ACh systems. The activity of ChAT has been found to be normal or reduced in the striatum in PD patients. Furthermore, the basal ganglia are interconnected with the pedunculopontine nucleus (PPN). The PPN is thought to be involved in the initiation and modulation of gait and other stereotyped movements. In PD patients, the loss of cholinergic neurons in the PPN has been reported. The d crease in dopaminergic neuronal transmission in the basal ganglia might result in the inactivation of the PPN in PD patients and DD mice. The present results, together with previous findings, suggest that the ACh systems may be involved in the mechanisms that underlie DA-independent motor control, and motor impairment in PD patients may be ameliorated by DAindependent mechanisms. Although DA plays a prominent role in the pathogenesis and treatment of schizophrenia, several lines of evidence suggest an important role for the cholinergic system in the pathophysiology of schizophrenia. Hyperactivity induced by muscarinic receptor antagonists has been suggested to model antimuscarinic psychosis and cholinergic-related psychosis in schizophrenia. Hyperactivity in DD mice was ameliorated by a muscarinic receptor agonist in the present study, suggesting that such hyperactivity may be induced by similar mechanisms that underlie cholinergic-related psychosis in schizophrenia. DD mice might be useful for the identification of the neuronal mechanisms involved in cholinergic-related psychosis in schizophrenia.</style></abstract><notes><style face="normal" font="default" size="100%">Neuropsychopharmacology</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=71278341</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>74</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">74</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ikeda, M.</style></author><author><style face="normal" font="default" size="100%">Mori, E.</style></author><author><style face="normal" font="default" size="100%">Kosaka, K.</style></author><author><style face="normal" font="default" size="100%">Iseki, E.</style></author><author><style face="normal" font="default" size="100%">Hashimoto, M.</style></author><author><style face="normal" font="default" size="100%">Matsukawa, N.</style></author><author><style face="normal" font="default" size="100%">Matsuo, K.</style></author><author><style face="normal" font="default" size="100%">Nakagawa, M.</style></author><author><style face="normal" font="default" size="100%">Katayama, S.</style></author><author><style face="normal" font="default" size="100%">Higashi, Y.</style></author><author><style face="normal" font="default" size="100%">Yamada, T.</style></author><author><style face="normal" font="default" size="100%">Maruki, Y.</style></author><author><style face="normal" font="default" size="100%">Orimo, S.</style></author><author><style face="normal" font="default" size="100%">Yoshiiwa, A.</style></author><author><style face="normal" font="default" size="100%">Hanyu, H.</style></author><author><style face="normal" font="default" size="100%">Yokochi, M.</style></author><author><style face="normal" font="default" size="100%">Kimura, T.</style></author><author><style face="normal" font="default" size="100%">Mizoguchi, K.</style></author><author><style face="normal" font="default" size="100%">Nakanishi, A.</style></author><author><style face="normal" font="default" size="100%">Tsukamoto, T.</style></author><author><style face="normal" font="default" size="100%">Taniguchi, N.</style></author><author><style face="normal" font="default" size="100%">Okamoto, K.</style></author><author><style face="normal" font="default" size="100%">Kitamura, T.</style></author><author><style face="normal" font="default" size="100%">Nakano, Y.</style></author><author><style face="normal" font="default" size="100%">Kato, T.</style></author><author><style face="normal" font="default" size="100%">Shimada, K.</style></author><author><style face="normal" font="default" size="100%">Hiji, M.</style></author><author><style face="normal" font="default" size="100%">Yoshiyama, Y.</style></author><author><style face="normal" font="default" size="100%">Kitamura, Y.</style></author><author><style face="normal" font="default" size="100%">Takahashi, S.</style></author><author><style face="normal" font="default" size="100%">Akishita, M.</style></author><author><style face="normal" font="default" size="100%">Washimi, Y.</style></author><author><style face="normal" font="default" size="100%">Yamamoto, Y.</style></author><author><style face="normal" font="default" size="100%">Kobayashi, M.</style></author><author><style face="normal" font="default" size="100%">Udaka, F.</style></author><author><style face="normal" font="default" size="100%">Osaki, Y.</style></author><author><style face="normal" font="default" size="100%">Hino, H.</style></author><author><style face="normal" font="default" size="100%">Kanda, T.</style></author><author><style face="normal" font="default" size="100%">Kishimoto, T.</style></author><author><style face="normal" font="default" size="100%">Oguro, H.</style></author><author><style face="normal" font="default" size="100%">Matsuoka, T.</style></author><author><style face="normal" font="default" size="100%">Tsugu, Y.</style></author><author><style face="normal" font="default" size="100%">Fujii, N.</style></author><author><style face="normal" font="default" size="100%">Kawase, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-term safety and efficacy of donepezil in patients with dementia with lewy bodies: Results from a 52-week, open-label, multicenter extension study</style></title><secondary-title><style face="normal" font="default" size="100%">Dementia and Geriatric Cognitive Disorders</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Dementia and Geriatric Cognitive Disorders</style></full-title></periodical><pages><style face="normal" font="default" size="100%">229-241</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">3-4</style></number><keywords><keyword><style face="normal" font="default" size="100%">acute pancreatitis/si [Side Effect] // aged // article // asphyxia/si [Side Effect] // atrioventricular block/si [Side Effect] // blood pressure // bradycardia/si [Side Effect] // caregiver burden // chronic drug administration // cognition // compressi</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00915998</style></accession-num><abstract><style face="normal" font="default" size="100%">Background/Aims: To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB). Methods: This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized, placebo-controlled trial (RCT), patients started treatment with 3 mg of donepezil daily for 2 weeks, followed by 5 mg daily for the remaining 50 weeks. Cognitive function, behavioral and psychiatric symptoms, cognitive fluctuations, and caregiver burden were assessed using the Mini-Mental State Examination, Neuropsychiatric Inventory, Cognitive Fluctuation Inventory, and the Zarit Caregiver Burden Interview, respectively. Safety parameters were monitored throughout. Results: In total, 108 patients were enrolled in the study. Cognitive function and dementia-related behavioral symptoms, including cognitive fluctuations, were improved after the start of donepezil treatment, and improvement was maintained for 52 weeks. Reduction in caregiver burden observed in the preceding RCT returned to the baseline level at 52 weeks. There was no significant imbalance in the incidence of adverse events (AEs) by onset time, and delayed AE onset induced by the long-term administration of donepezil was unlikely to appear. Conclusion: The long-term administration of donepezil at 5 mg/day was well tolerated in patients with DLB and is expected to exhibit lasting effects, improving impaired cognitive function and psychiatric symptoms up to 52 weeks. 2013 S. Karger AG, Basel.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/998/CN-00915998/frame.html</style></url><url><style face="normal" font="default" size="100%">http://www.karger.com/Article/Pdf/351672</style></url></related-urls><pdf-urls><url>internal-pdf://1734575198/Ikeda-2013-Long-term safety and.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1159/000351672</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>69</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">69</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kano, O.</style></author><author><style face="normal" font="default" size="100%">Ito, H.</style></author><author><style face="normal" font="default" size="100%">Takazawa, T.</style></author><author><style face="normal" font="default" size="100%">Kawase, Y.</style></author><author><style face="normal" font="default" size="100%">Murata, K.</style></author><author><style face="normal" font="default" size="100%">Iwamoto, K.</style></author><author><style face="normal" font="default" size="100%">Nagaoka, T.</style></author><author><style face="normal" font="default" size="100%">Hirayama, T.</style></author><author><style face="normal" font="default" size="100%">Miura, K.</style></author><author><style face="normal" font="default" size="100%">Nagata, R.</style></author><author><style face="normal" font="default" size="100%">Kiyozuka, T.</style></author><author><style face="normal" font="default" size="100%">Aoyagi, J.</style></author><author><style face="normal" font="default" size="100%">Sato, R.</style></author><author><style face="normal" font="default" size="100%">Eguchi, T.</style></author><author><style face="normal" font="default" size="100%">Ikeda, K.</style></author><author><style face="normal" font="default" size="100%">Iwasaki, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer&apos;s disease receiving donepezil</style></title><secondary-title><style face="normal" font="default" size="100%">Neuropsychiatric Disease and Treatment</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuropsychiatric Disease and Treatment</style></full-title></periodical><pages><style face="normal" font="default" size="100%">259-265</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><keywords><keyword><style face="normal" font="default" size="100%">aged // agitation // Alzheimer disease/dt [Drug Therapy] // article // caregiver // cognition // Cohen Mansfield agitation inventory // controlled study // disability assessment for dementia // disease severity // drug dose comparison // drug dose incre</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00911793</style></accession-num><abstract><style face="normal" font="default" size="100%">Clinical trials have shown the benefits of acetylcholinesterase inhibitors, such as donepezil and galantamine, and an N-methyl-d-aspartate receptor antagonist, memantine, in patients with Alzheimer&apos;s disease (AD). However, little is known regarding the effects of switching from donepezil 5 mg/day to galantamine 16 or 24 mg/day, or regarding the effects of adding memantine to established therapy compared with increasing the dose of donepezil. This report discusses two studies conducted to evaluate treatment with galantamine and memantine with respect to cognitive benefits and caregiver evaluations in patients with AD receiving donepezil 5 mg/day for more than 6 months. Patients with mild or moderate AD (scores 10-22 on the Mini-Mental State Examination) were enrolled in the Galantamine Switch study and switched to galantamine (maximum doses 16 mg versus 24 mg). Patients with moderate to severe AD (MiniMental State Examination scores 3-14) were enrolled in the Donepezil Increase versus Additional Memantine study and either had their donepezil dose increased to 10 mg/day or memantine 20 mg/day added to their existing donepezil dose. Patients received the study treatment for 28 weeks and their Disability Assessment for Dementia, Mental Function Impairment Scale, Cohen-Mansfield Agitation Inventory, and Neuropsychiatric Inventory scores were assessed with assistance from their caregivers. For the Galantamine Switch study after 8 weeks, agitation evaluated by the Cohen-Mansfeld Agitation Inventory improved in both the 16 mg and 24 mg groups compared with baseline. However, there were no significant differences between the two galantamine groups. Agitation was also less in patients in the additional memantine group than in the donepezil increase group. In summary, switching to galantamine from donepezil and addition of memantine in patients with AD receiving donepezil were both safe and meaningful treatment options, and particularly efficacious for suppression of agitation. 2013 Kano et al, publisher and licensee Dove Medical Press Ltd.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/793/CN-00911793/frame.html</style></url><url><style face="normal" font="default" size="100%">http://www.dovepress.com/getfile.php?fileID=15211</style></url></related-urls><pdf-urls><url>internal-pdf://1101513929/Kano-2013-Clinically meaningfu.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.2147/NDT.S40682</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>101</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">101</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karlsson, J. A.</style></author><author><style face="normal" font="default" size="100%">Neovius, M.</style></author><author><style face="normal" font="default" size="100%">Nilsson, J. A.</style></author><author><style face="normal" font="default" size="100%">Petersson, I. F.</style></author><author><style face="normal" font="default" size="100%">Bratt, J.</style></author><author><style face="normal" font="default" size="100%">Vollenhoven, R. F.</style></author><author><style face="normal" font="default" size="100%">Ernestam, S.</style></author><author><style face="normal" font="default" size="100%">Geborek, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of the Rheumatic Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of the Rheumatic Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1927-1933</style></pages><volume><style face="normal" font="default" size="100%">72</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">adult // article // combination chemotherapy // comparative effectiveness // controlled study // disease activity // dose response // drug dose increase // drug efficacy // drug substitution // drug withdrawal // female // follow up // human // major cl</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00911330</style></accession-num><abstract><style face="normal" font="default" size="100%">Objective: To compare EuroQol 5-Dimensions (EQ-5D) utility and quality-adjusted life-years (QALYs) in patients with early, methotrexate (MTX) refractory rheumatoid arthritis (RA), randomised to addition of infliximab (IFX) or sulfasalazine and hydroxychloroquine (SSZ+HCQ). Methods: RA-patients with symptoms &lt;1 year were enrolled between 2002 and 2005 at 15 Swedish centres. After 3-4 months of MTX monotherapy, patients with a remaining DAS28&gt;3.2 were randomised to addition of IFX or SSZ+HCQ and followed for 21 months. EQ-5D profiles were collected every 3 months. Between-group comparisons of utility change and accumulated QALYs were performed, using last observation carried forward (LOCF) following protocol breach. Missing data were imputed by linear interpolation or LOCF. Sensitivity analyses applying baseline observation carried forward (BOCF) or restricted to completers were conducted. Results: Of 487 patients initially enrolled, 128 and 130 were randomised to IFX or SSZ+HCQ, respectively. Mean utility in the IFX and SSZ+HCQ groups increased from 0.52 (SD 0.27) and 0.55 (SD 0.27) at randomisation to 0.66 (SD 0.25) and 0.63 (SD 0.27) at 21 months (adjusted mean difference favouring IFX 0.04; 95% CI -0.01, 0.09; p=0.15). Average accumulated QALYs were 1.10 (SD 0.37) and 1.07 (SD 0.42) in the IFX and SSZ+HCQ groups, respectively (adjusted mean difference favouring IFX 0.07; 95%CI -0.01, 0.14; p=0.07). BOCF analysis showed similar results, while differences were reversed, though remained statistically non-significant among completers. Dropout rates in the IFX/SSZ+HCQ groups were 30%/43% (p=0.01). Conclusions Comparing addition of IFX or SSZ+HCQ to MTX in active early RA, no statistically significant differences in utility or QALY gain could be detected over 21 months.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/330/CN-00911330/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ard.bmj.com/content/72/12/1927.long</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1136/annrheumdis-2012-202062</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>114</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">114</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Keefe, R. S. E.</style></author><author><style face="normal" font="default" size="100%">Kraemer, H. C.</style></author><author><style face="normal" font="default" size="100%">Epstein, R. S.</style></author><author><style face="normal" font="default" size="100%">Frank, E.</style></author><author><style face="normal" font="default" size="100%">Haynes, G.</style></author><author><style face="normal" font="default" size="100%">Laughren, T. P.</style></author><author><style face="normal" font="default" size="100%">McNulty, J.</style></author><author><style face="normal" font="default" size="100%">Reed, S. D.</style></author><author><style face="normal" font="default" size="100%">Sanchez, J.</style></author><author><style face="normal" font="default" size="100%">Leon, A. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Duke University Medical Center, Durham, NC, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials</style></title></titles><pages><style face="normal" font="default" size="100%">4S-19S</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">(Keefe) Duke University Medical Center, Durham, NC, United States</style></number><edition><style face="normal" font="default" size="100%">5-6</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">central nervous system disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical decision making</style></keyword><keyword><style face="normal" font="default" size="100%">*clinically meaningful effect</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">comparative effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">cost control</style></keyword><keyword><style face="normal" font="default" size="100%">cost effectiveness analysis</style></keyword><keyword><style face="normal" font="default" size="100%">cost utility analysis</style></keyword><keyword><style face="normal" font="default" size="100%">depression/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">depression/th [Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*effect size</style></keyword><keyword><style face="normal" font="default" size="100%">health care cost</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">metabolic disorder/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">numbers needed to treat</style></keyword><keyword><style face="normal" font="default" size="100%">orthostatic hypotension/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">personalized medicine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo effect</style></keyword><keyword><style face="normal" font="default" size="100%">Positive and Negative Syndrome Scale</style></keyword><keyword><style face="normal" font="default" size="100%">*psychopharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">psychotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">quality adjusted life year</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">*randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">reimbursement</style></keyword><keyword><style face="normal" font="default" size="100%">sample size</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">statistical significance</style></keyword><keyword><style face="normal" font="default" size="100%">study design</style></keyword><keyword><style face="normal" font="default" size="100%">4 aminopyridine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">central nervous system agents</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">imipramine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">imipramine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">*psychotropic agent</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin uptake inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">threo 3,4 dihydroxyphenylserine/dt [Drug Therapy]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">United States</style></pub-location><publisher><style face="normal" font="default" size="100%">Matrix Medical Communications (1595 Paoli Pike, Suite 103, West Chester PA 19380, United States)</style></publisher><isbn><style face="normal" font="default" size="100%">2158-8333</style></isbn><abstract><style face="normal" font="default" size="100%">Objective: This article captures the proceedings of a meeting aimed at defining clinically meaningful effects for use in randomized controlled trials for psychopharmacological agents. Design: Experts from a variety of disciplines defined clinically meaningful effects from their perspectives along with viewpoints about how to design and interpret randomized controlled trials. Setting: The article offers relevant, practical, and sometimes anecdotal information about clinically meaningful effects and how to interpret them. Participants: The concept for this session was the work of co-chairs Richard Keefe and the late Andy Leon. Faculty included Richard Keefe, PhD; James McNulty, AbScB; Robert S. Epstein, MD, MS; Shelby D. Reed, PhD; Juan Sanchez, MD; Ginger Haynes, PhD; Andrew C. Leon, PhD; Helena Chmura Kraemer, PhD; Ellen Frank, PhD, and Kenneth L. Davis, MD. Results: The term clinically meaningful effect is an important aspect of designing and interpreting randomized controlled trials but can be particularly difficult in the setting of psychopharmacology where effect size may be modest, particularly over the short term, because of a strong response to placebo. Payers, regulators, patients, and clinicians have different concerns about clinically meaningful effects and may describe these terms differently. The use of moderators in success rate differences may help better delineate clinically meaningful effects. Conclusion: There is no clear consensus on a single definition for clinically meaningful differences in randomized controlled trials, and investigators must be sensitive to specific concerns of stakeholders in psychopharmacology in order to design and execute appropriate clinical trials.</style></abstract><notes><style face="normal" font="default" size="100%">Innovations in Clinical Neuroscience</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://innovationscns.com/defining-a-clinically-meaningful-effect-for-the-design-and-interpretation-of-randomized-controlled-trials/</style></url><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013662858</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>129</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">129</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klinkenberg, Inge</style></author><author><style face="normal" font="default" size="100%">Sambeth, Anke</style></author><author><style face="normal" font="default" size="100%">Blokland, Arjan</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Adler, Adler Bickford Bickford-Wimer Bolden Borg Boutros Boutros Bramon Brockhaus-Dumke Buchwald Buchwald Bymaster Cadenhead Campbell Cancelli Caulfield de Bruin De Wilde Dudar Fein Golob Irimajiri Jann Jessen Jin Jin Katayama Kathmann Klinkenberg Klinkenberg Krause Lamberti Legault Levey Luntz-Leybman Mesulam Miyazato Miyazato Miyazato Nagamoto Nagamoto Olincy Oranje Patterson Pekkonen Potier Radek Sambeth Simons Stevens Stevens Teneud Thomas Wildeboer Woolf Woolf Yokogawa Zouridakis</style></author></secondary-authors></contributors><auth-address><style face="normal" font="default" size="100%">Klinkenberg, Inge: Faculty of Psychology and Neuroscience, Department of Neuropsychology and Psychopharmacology, Maastricht University, P.O. Box 616, Maastricht, Netherlands, 6200 MD, inge.klinkenberg@maastrichtuniversity.nl&#xD;Klinkenberg, Inge: inge.klinkenberg@maastrichtuniversity.nl</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cholinergic gating of hippocampal auditory evoked potentials in freely moving rats</style></title></titles><pages><style face="normal" font="default" size="100%">988-997</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">Adler, L.E., Pachtman, E., Franks, R.D., Pecevich, M., Waldo, M.C., &amp; Freedman, R. (1982). Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol. Psychiatry, 17, 639-654.71044171983-01116-001</style></number><edition><style face="normal" font="default" size="100%">8</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Auditory Evoked Potentials</style></keyword><keyword><style face="normal" font="default" size="100%">*Hippocampus</style></keyword><keyword><style face="normal" font="default" size="100%">*Scopolamine</style></keyword><keyword><style face="normal" font="default" size="100%">*Sensory Gating</style></keyword><keyword><style face="normal" font="default" size="100%">Neurochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">Netherlands</style></pub-location><publisher><style face="normal" font="default" size="100%">Elsevier Science&#xD;Netherlands</style></publisher><isbn><style face="normal" font="default" size="100%">0924-977X</style></isbn><abstract><style face="normal" font="default" size="100%">As perturbations in auditory filtering appear to be a candidate trait marker of schizophrenia, there has been considerable interest in the development of translational rat models to elucidate the underlying neural and neurochemical mechanisms involved in sensory gating. This is the first study to investigate the effects of the non-selective muscarinic antagonist scopolamine, the muscarinic M1 antagonist biperiden and the cholinesterase inhibitor donepezil (also in combination with scopolamine and biperiden) on auditory evoked potentials (AEPs) and sensory gating. In the saline condition, only the N50 peak displayed sensory gating. Scopolamine and biperiden both disrupted sensory gating by increasing N50 amplitude for the S2 click. Donepezil was able to fully reverse the effects of biperiden on N50 sensory gating, but had residual effects when combined with scopolamine; i.e., it enhanced sensory gating by increasing N50 amplitude of the S1 stimulus. Donepezil by itself improved sensory gating by enhancing N50 amplitude of S1, and reducing N50 amplitude of the S2 click. In conclusion, due to its relatively more selective effects biperiden is to be preferred over scopolamine as a means for pharmacologically inducing cholinergic impairments in auditory processing in healthy rats. Changes in auditory processing and sensory gating induced by cholinergic drugs may serve as a translational model for aging instead of schizophrenia. (PsycINFO Database Record (c) 2013 APA, all rights reserved) (journal abstract)</style></abstract><notes><style face="normal" font="default" size="100%">European Neuropsychopharmacology&#xD;http://dx.doi.org/10.1016/j.euroneuro.2012.08.014</style></notes><work-type><style face="normal" font="default" size="100%">Electrophysiology 2530</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=psyc7&amp;NEWS=N&amp;AN=2012-24927-001</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>124</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">124</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Knapp, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Knapp, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, United Kingdom. E-mail: m.knapp@lse.ac.uk</style></auth-address><titles><title><style face="normal" font="default" size="100%">Future of dementia care: An economic perspective</style></title></titles><pages><style face="normal" font="default" size="100%">23-26</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">(Knapp) London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, United Kingdom</style></number><edition><style face="normal" font="default" size="100%">1</style></edition><keywords><keyword><style face="normal" font="default" size="100%">aging</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">clinical research</style></keyword><keyword><style face="normal" font="default" size="100%">cost effectiveness analysis</style></keyword><keyword><style face="normal" font="default" size="100%">degenerative disease</style></keyword><keyword><style face="normal" font="default" size="100%">*dementia/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">health care cost</style></keyword><keyword><style face="normal" font="default" size="100%">health care policy</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">medical research</style></keyword><keyword><style face="normal" font="default" size="100%">note</style></keyword><keyword><style face="normal" font="default" size="100%">patient care</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia</style></keyword><keyword><style face="normal" font="default" size="100%">social care</style></keyword><keyword><style face="normal" font="default" size="100%">social stigma</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">memantine/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">memantine/dt [Drug Therapy]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">United Kingdom</style></pub-location><publisher><style face="normal" font="default" size="100%">Future Medicine Ltd. (2nd Albert Place, Finchley Central, London N3 1QB, United Kingdom)</style></publisher><isbn><style face="normal" font="default" size="100%">1758-2024</style></isbn><notes><style face="normal" font="default" size="100%">Neurodegenerative Disease Management</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013077851</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>117</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">117</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lam, J.</style></author><author><style face="normal" font="default" size="100%">Coleman, N.</style></author><author><style face="normal" font="default" size="100%">Garing, A. L. A.</style></author><author><style face="normal" font="default" size="100%">Wulff, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">H. Wulff, University of California, Department of Pharmacology, 451 Health Sciences Drive, Davis, CA 95616, United States. E-mail: hwulff@ucdavis.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases</style></title></titles><pages><style face="normal" font="default" size="100%">1203-1220</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">(Lam, Coleman, Garing, Wulff) University of California, Department of Pharmacology, 451 Health Sciences Drive, Davis, CA 95616, United States</style></number><edition><style face="normal" font="default" size="100%">10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">action potential</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol abuse</style></keyword><keyword><style face="normal" font="default" size="100%">alcoholism</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">amygdaloid nucleus</style></keyword><keyword><style face="normal" font="default" size="100%">ataxia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">behavior change</style></keyword><keyword><style face="normal" font="default" size="100%">cell membrane depolarization</style></keyword><keyword><style face="normal" font="default" size="100%">cerebellar ataxia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*degenerative disease</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">drug targeting</style></keyword><keyword><style face="normal" font="default" size="100%">electric shock/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">hippocampus</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">learning</style></keyword><keyword><style face="normal" font="default" size="100%">memory</style></keyword><keyword><style face="normal" font="default" size="100%">*mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">multiple sclerosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">nerve cell excitability</style></keyword><keyword><style face="normal" font="default" size="100%">neuroprotection</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">protein expression</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">sedation</style></keyword><keyword><style face="normal" font="default" size="100%">spinal cerebellar ataxia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">structure activity relation</style></keyword><keyword><style face="normal" font="default" size="100%">synaptic transmission</style></keyword><keyword><style face="normal" font="default" size="100%">1 ebio/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">1 ebio/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">1 ebio/sc [Subcutaneous Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">amantadine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">amantadine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">apamin/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">apomorphine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">apomorphine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">benzatropine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">benzatropine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">bromocriptine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">bromocriptine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">carbamic acid derivative/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">entacapone/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">entacapone/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">gw 542573x/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">levodopa/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">levodopa/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">memantine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">memantine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">ns 13001/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">ns 13001/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">ns 309/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">ns 8593/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">*potassium channel stimulating agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*potassium channel stimulating agent/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">*potassium channel stimulating agent/sc [Subcutaneous Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">pramipexole/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">pramipexole/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">riluzole/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">riluzole/an [Drug Analysis]</style></keyword><keyword><style face="normal" font="default" size="100%">riluzole/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">ropinirole/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">ropinirole/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">rotigotine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">rotigotine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">selegiline/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">selegiline/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">ska 31/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">ska 31/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">*small conductance calcium activated potassium channel/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">*small conductance calcium activated potassium channel activator/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*small conductance calcium activated potassium channel activator/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">tolcapone/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">tolcapone/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">trihexyphenidyl/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">trihexyphenidyl/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">unindexed drug</style></keyword><keyword><style face="normal" font="default" size="100%">zolpidem/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">zolpidem/pd [Pharmacology]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">United Kingdom</style></pub-location><publisher><style face="normal" font="default" size="100%">Informa Healthcare (69-77 Paul Street, London EC2A 4LQ, United Kingdom)</style></publisher><isbn><style face="normal" font="default" size="100%">1472-8222</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: KCa2 or small-conductance Ca2+-activated K + channels (SK) are expressed in many areas of the central nervous system where they participate in the regulation of neuronal afterhyperpolarization and excitability, and also serve as negative feedback regulators on the glutamate-NMDA pathway. Areas covered: This review focuses on the role of KCa2 channels in learning and memory and their potential as therapeutic targets for Alzheimer&apos;s and Parkinson&apos;s disease, ataxia, schizophrenia and alcohol dependence. Expert opinion: There currently exists relatively solid evidence supporting the use of KCa2 activators for ataxia. Genetic KCa2 channel suppression in deep cerebellar neurons induces ataxia, while KCa2 activators like 1-EBIO, SKA-31 and NS13001 improve motor deficits in mouse models of episodic ataxia (EA) and spinal cerebellar ataxia (SCA). Use of KCa2 activators for ataxia is further supported by a report that riluzole improves ataxia in a small clinical trial. Based on accumulating literature evidence, KCa2 activators further appear attractive for the treatment of alcohol dependence and withdrawal. Regarding Alzheimer&apos;s disease, Parkinson&apos;s disease and schizophrenia, further research, including long-term studies in disease relevant animal models, will be needed to determine whether KCa2 channels constitute valid targets and whether activators or inhibitors would be needed to positively affect disease outcomes. Informa UK, Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Expert Opinion on Therapeutic Targets</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013600782</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>95</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">95</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, H.</style></author><author><style face="normal" font="default" size="100%">Yang, H. L.</style></author><author><style face="normal" font="default" size="100%">Xu, J. W.</style></author><author><style face="normal" font="default" size="100%">Wang, J. Z.</style></author><author><style face="normal" font="default" size="100%">Nie, R. H.</style></author><author><style face="normal" font="default" size="100%">Li, C. F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: An open-label randomized and non-inferiority trial in Yunnan Province, China</style></title><secondary-title><style face="normal" font="default" size="100%">Malaria Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Malaria Journal</style></full-title></periodical><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">abdominal pain/si [Side Effect] // adolescent // anorexia/si [Side Effect] // article // child // China // controlled study // diarrhea/si [Side Effect] // dizziness/si [Side Effect] // drug efficacy // drug safety // female // follow up // headache/si</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">Cn-00911457</style></accession-num><abstract><style face="normal" font="default" size="100%">Background:Plasmodium vivax is the main malaria parasite in China, and China is now making efforts to eliminate malaria by 2020. Radical cure of vivax malaria is one of challenges for malaria elimination. The purpose is to evaluate the efficacy and safety of artemisinin-naphthoquine (ANQ) versus chloroquine-primaquine (CQ-PQ) in treatment of vivax malaria in Yunnan Province, China. Methods. An open-label randomized and non-inferiority design, eligible patients with monoinfections of P. vivax were randomly assigned to receive either a total target dose of ANQ 24.5 mg/kg (naphthoquine 7 mg/kg and artemisinin 17.5 mg/kg), once a day for three days, or a total CQ dose of 24 mg base/kg, once a day for three days plus a PQ dose of 0.45 mg base/kg/day, once a day for eight days. Patients were followed up for one year. The difference in efficacy between ANQ and CQ-PQ was compared via Wilson&apos;s test. Results: By day 42, the number of patients free of recurrence was 125 (98.4%; 95% Confidence interval, 94.4-99.8%) for ANQ arm and 123 (96.1%; 95%CI, 91.1-98.7%) for CQ-PQ, and non-significant (P = 0.4496). By day 365, the number was 101 (79.5%; 95%CI, 71.8-85.9%) for ANQ and 106 (82.8%; 95%CI, 75.1-88.9%) for CQ-PQ, and non-significant (P = 0.610). So the proportions of patients free of recurrence had no significant difference between ANQ and CQ-PQ groups by day 28, 42 and 365; compared with CQ-PQ, the side effect of ANQ was mild. Conclusion: ANQ is non-inferior to CQ-PQ in terms of patients free of recurrence, and safer than CQ-PQ. 2013 Liu et al.; licensee BioMed Central Ltd.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/457/CN-00911457/frame.html</style></url><url><style face="normal" font="default" size="100%">http://www.malariajournal.com/content/pdf/1475-2875-12-409.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2953234494/Liu-2013-Artemisinin-naphthoq.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/1475-2875-12-409</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>90</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">90</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lopez-del-Hoyo, Y.</style></author><author><style face="normal" font="default" size="100%">Olivan, B.</style></author><author><style face="normal" font="default" size="100%">Luciano, J. V.</style></author><author><style face="normal" font="default" size="100%">Mayoral, F.</style></author><author><style face="normal" font="default" size="100%">Roca, M.</style></author><author><style face="normal" font="default" size="100%">Gili, M.</style></author><author><style face="normal" font="default" size="100%">Andres, E.</style></author><author><style face="normal" font="default" size="100%">Serrano-Blanco, A.</style></author><author><style face="normal" font="default" size="100%">Collazo, F.</style></author><author><style face="normal" font="default" size="100%">Araya, R.</style></author><author><style face="normal" font="default" size="100%">Banos, R.</style></author><author><style face="normal" font="default" size="100%">Botella, C.</style></author><author><style face="normal" font="default" size="100%">Magallon, R.</style></author><author><style face="normal" font="default" size="100%">Garcia-Campayo, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Low intensity vs. self-guided Internet-delivered psychotherapy for major depression: A multicenter, controlled, randomized study</style></title></titles><keywords><keyword><style face="normal" font="default" size="100%">adult // aged // article // Beck Depression Inventory // Client Service Receipt Inventory // controlled study // disease severity // female // health care delivery // health service // human // low intensity delivered psychotherapy // major clinical stu</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00907833</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Major depression will become the second most important cause of disability in 2020. Computerized cognitive-behaviour therapy could be an efficacious and cost-effective option for its treatment. No studies on cost-effectiveness of low intensity vs self-guided psychotherapy has been carried out. The aim of this study is to assess the efficacy of low intensity vs self-guided psychotherapy for major depression in the Spanish health system.Methods: The study is made up of 3 phases: 1.- Development of a computerized cognitive-behaviour therapy for depression tailored to Spanish health system. 2.- Multicenter controlled, randomized study: A sample (N=450 patients) with mild/moderate depression recruited in primary care. They should have internet availability at home, not receive any previous psychological treatment, and not suffer from any other severe somatic or psychological disorder. They will be allocated to one of 3 treatments: a) Low intensity Internet-delivered psychotherapy + improved treatment as usual (ITAU) by GP, b) Self-guided Internet-delivered psychotherapy + ITAU or c) ITAU. Patients will be diagnosed with MINI psychiatric interview. Main outcome variable will be Beck Depression Inventory. It will be also administered EuroQol 5D (quality of life) and Client Service Receipt Inventory (consume of health and social services). Patients will be assessed at baseline, 3 and 12 months. An intention to treat and a per protocol analysis will be performed.Discussion: The comparisons between low intensity and self-guided are infrequent, and also a comparative economic evaluation between them and compared with usual treatment in primary. The strength of the study is that it is a multicenter, randomized, controlled trial of low intensity and self-guided Internet-delivered psychotherapy for depression in primary care, being the treatment completely integrated in primary care setting.Trial registration: Clinical Trials NCT01611818. 2013 Lopez-del-Hoyo et al.; licensee BioMed Central Ltd.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/833/CN-00907833/frame.html</style></url><url><style face="normal" font="default" size="100%">http://www.biomedcentral.com/content/pdf/1471-244X-13-21.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://4084960732/Lopez-del-Hoyo-2013-Low intensity vs. se.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/1471-244X-13-21</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>96</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">96</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mahfouz, R. A.</style></author><author><style face="normal" font="default" size="100%">Charafeddine, K. M.</style></author><author><style face="normal" font="default" size="100%">Tanios, R. F.</style></author><author><style face="normal" font="default" size="100%">Karaky, N. M.</style></author><author><style face="normal" font="default" size="100%">Abdul Khalik, R. N.</style></author><author><style face="normal" font="default" size="100%">Daher, R. T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Apolipoprotein E gene polymorphisms in Lebanese with hypercholesterolemia</style></title><secondary-title><style face="normal" font="default" size="100%">Gene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Gene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">84-88</style></pages><volume><style face="normal" font="default" size="100%">522</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">adult // aged // article // blood sampling // clinical article // clinical assessment // controlled study // DNA polymorphism // female // gene frequency // genotype // human // hypercholesterolemia // Lebanon // lipid analysis // male // priority journ</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00907292</style></accession-num><abstract><style face="normal" font="default" size="100%">Apolipoprotein E (ApoE) has an important role in the metabolism of lipids through its major isoforms (2, 3, 4). In particular, ApoE 4, has been considered as a major genetic risk factor for cardiovascular diseases (CVD). The aim of our study is to investigate the frequency of ApoE gene polymorphisms (rs 429358C &gt; T, rs 7412C &gt; T) and their relationship to lipid parameters in a group of Lebanese hypercholesterolemic subjects (22 males and 24 females, aged 25-80. years). Lipid profile, apolipoproteins A-I and B were determined using fasting serum samples; and molecular analysis of ApoE polymorphisms using blood in EDTA tubes. The distribution of the four ApoE genotypes detected in this study was: 3/3 (73.9%), 3/4 (17.4%), 2/3 (6.5%), and 2/4 (2.2%) resulting in allelic frequencies for 2, 3 and 4 of 4.3%, 85.9% and 9.8%, respectively. No association was determined among any of the lipid parameters, gender and ApoE genotypes. Lipid parameters were not statistically different among various ApoE genotypes (p &gt; 0.05). ApoE 2 frequency was found to be lower than that previously reported for healthy Lebanese (7.2%). CVD is one of the major leading causes of mortality in Lebanon with a reported prevalence of 12.2% in males and 7.7% in females, which incidentally agrees with our finding regarding 4 allelic frequency of 13.6% in males and 6.3% in females. Consequently, larger prospective studies are recommended to highlight the correlation of ApoE polymorphisms to other biochemical and environmental factors involved in CVD. 2013 Elsevier B.V.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/292/CN-00907292/frame.html</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.gene.2013.03.019</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>88</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">88</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Molho, E.</style></author><author><style face="normal" font="default" size="100%">Barba, A.</style></author><author><style face="normal" font="default" size="100%">Feustel, P.</style></author><author><style face="normal" font="default" size="100%">Higgins, D.</style></author><author><style face="normal" font="default" size="100%">Factor, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Double-blind, placebo-controlled trial of donepezil for dementia or mild cognitive impairment in Parkinson disease</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Parkinson&apos;s Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Parkinson&apos;s Disease</style></full-title></periodical><pages><style face="normal" font="default" size="100%">106</style></pages><volume><style face="normal" font="default" size="100%">Conference: 3rd World Parkinson Congress Montreal, QC Canada. Conference Start: 20131001 Conference End: 20131004. Conference Publication:</style></volume><number><style face="normal" font="default" size="100%">var.pagings</style></number><keywords><keyword><style face="normal" font="default" size="100%">Sr-dementia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">Cn-00883324</style></accession-num><work-type><style face="normal" font="default" size="100%">Journal: Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/324/CN-00883324/frame.html</style></url><url><style face="normal" font="default" size="100%">http://iospress.metapress.com/content/y146585107g14028/fulltext.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://4059243604/Molho-2013-Double-blind, placeb.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.3233/JPD-139905</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>80</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">80</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nct,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A multicenter, randomized, open-label, prospective study to estimate the add-on effects of memantine as Ebixa oral pump on language in moderate to severe Alzheimer&apos;s disease patients already receiving donepezil</style></title><secondary-title><style face="normal" font="default" size="100%">ClinicalTrials.gov [http://clinicaltrials.gov]</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ClinicalTrials.gov [http://clinicaltrials.gov]</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Sr-dementia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">Cn-00872145</style></accession-num><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/145/CN-00872145/frame.html</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>81</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">81</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nct,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild - moderate Alzheimer&apos;s disease treated with donepezil</style></title><secondary-title><style face="normal" font="default" size="100%">ClinicalTrials.gov [http://clinicaltrials.gov]</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ClinicalTrials.gov [http://clinicaltrials.gov]</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Sr-dementia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">Cn-00872167</style></accession-num><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/167/CN-00872167/frame.html</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>83</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">83</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nct,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of cerebrolysin and donepezil: a randomized, double-blind, controlled trial on efficacy and safety in patients with mild to moderate Alzheimer&apos;s disease</style></title><secondary-title><style face="normal" font="default" size="100%">ClinicalTrials.gov [http://clinicaltrials.gov]</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ClinicalTrials.gov [http://clinicaltrials.gov]</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Sr-dementia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">Cn-00872153</style></accession-num><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/153/CN-00872153/frame.html</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>85</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">85</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nct,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A seamless phase IIa/IIb, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of MK-7622 as an adjunctive therapy to donepezil for symptomatic treatment in subjects with Alzheimer&apos;s disease</style></title><secondary-title><style face="normal" font="default" size="100%">ClinicalTrials.gov [http://clinicaltrials.gov]</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ClinicalTrials.gov [http://clinicaltrials.gov]</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Sr-dementia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">Cn-00872165</style></accession-num><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/165/CN-00872165/frame.html</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>79</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">79</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pa, J.</style></author><author><style face="normal" font="default" size="100%">Berry, A. S.</style></author><author><style face="normal" font="default" size="100%">Compagnone, M.</style></author><author><style face="normal" font="default" size="100%">Boccanfuso, J.</style></author><author><style face="normal" font="default" size="100%">Greenhouse, I.</style></author><author><style face="normal" font="default" size="100%">Rubens, M. T.</style></author><author><style face="normal" font="default" size="100%">Johnson, J. K.</style></author><author><style face="normal" font="default" size="100%">Gazzaley, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cholinergic enhancement of functional networks in older adults with mild cognitive impairment</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of neurology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of neurology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">762-73</style></pages><volume><style face="normal" font="default" size="100%">73</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Brain [drug effects] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cholinesterase Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Indans [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Mild Cognitive Impairment [drug therapy] [physiopathology] [psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">Nerve Net [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Photic Stimulation [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperidines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Reaction Time [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Up-Regulation [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Sr-dementia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00871905</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: The importance of the cholinergic system for cognitive function has been well documented in animal and human studies. The objective of this study was to elucidate the cognitive and functional connectivity changes associated with enhanced acetylcholine levels. We hypothesized that older adults with mild memory deficits would show behavioral and functional network enhancements with an acetylcholinesterase inhibitor treatment (donepezil) when compared to a placebo control group. METHODS: We conducted a 3-month, double-blind, placebo-controlled study on the effects of donepezil in 27 older adults with mild memory deficits. Participants completed a delayed recognition memory task. Functional magnetic resonance imaging (fMRI) scans were collected at baseline prior to treatment and at 3-month follow-up while subjects were on a 10mg daily dose of donepezil or placebo. RESULTS: Donepezil treatment significantly enhanced the response time for face and scene memory probes when compared to the placebo group. A group-by-visit interaction was identified for the functional network connectivity of the left fusiform face area (FFA) with the hippocampus and inferior frontal junction, such that the treatment group showed increased connectivity over time when compared to the placebo group. Additionally, the enhanced functional network connectivity of the FFA and hippocampus significantly predicted memory response time at 3-month follow-up in the treatment group. INTERPRETATION: These findings suggest that increased cholinergic transmission improves goal-directed neural processing and cognitive ability and may serve to facilitate communication across functionally-connected attention and memory networks. Longitudinal fMRI is a useful method for elucidating the neural changes associated with pharmacological modulation and is a potential tool for monitoring intervention efficacy in clinical trials.</style></abstract><work-type><style face="normal" font="default" size="100%">Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov&apos;t</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/905/CN-00871905/frame.html</style></url><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/ana.23874/abstract?systemMessage=Wiley+Online+Library+will+be+disrupted+Saturday%2C+15+March+from+10%3A00-12%3A00+GMT+%2806%3A00-08%3A00+EDT%29+for+essential+maintenance</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">Pubmed 23447373</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/ana.23874</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>122</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">122</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Padala, P.</style></author><author><style face="normal" font="default" size="100%">Padala, K.</style></author><author><style face="normal" font="default" size="100%">Ghormley, C.</style></author><author><style face="normal" font="default" size="100%">Ledbetter, S.</style></author><author><style face="normal" font="default" size="100%">Pighee, V.</style></author><author><style face="normal" font="default" size="100%">Hartberg, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P. Padala, Central Arkansas Veterans Healthcare System, North Little Rock, AR, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Huperzine-a for memory problems in schizophrenia</style></title><tertiary-title><style face="normal" font="default" size="100%">2013 Annual Scientific Meeting of the American Geriatrics Society Grapevine, TX United States. Conference Start: 20130503 Conference End: 20130505&#xD;(var.pagings)</style></tertiary-title></titles><pages><style face="normal" font="default" size="100%">S179</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">(Padala, Padala, Ghormley, Ledbetter, Pighee, Hartberg.) Central Arkansas Veterans Healthcare System, North Little Rock, AR, United States</style></number><keywords><keyword><style face="normal" font="default" size="100%">*memory</style></keyword><keyword><style face="normal" font="default" size="100%">*schizophrenia</style></keyword><keyword><style face="normal" font="default" size="100%">*geriatrics</style></keyword><keyword><style face="normal" font="default" size="100%">*society</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">learning</style></keyword><keyword><style face="normal" font="default" size="100%">cognition</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">daily life activity</style></keyword><keyword><style face="normal" font="default" size="100%">clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">mood</style></keyword><keyword><style face="normal" font="default" size="100%">functional status</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">pilot study</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular accident</style></keyword><keyword><style face="normal" font="default" size="100%">head injury</style></keyword><keyword><style face="normal" font="default" size="100%">consensus</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">injury</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">open study</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">animal experiment</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">learning test</style></keyword><keyword><style face="normal" font="default" size="100%">herbal medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease</style></keyword><keyword><style face="normal" font="default" size="100%">*huperzine A</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">n methyl dextro aspartic acid receptor blocking agent</style></keyword><keyword><style face="normal" font="default" size="100%">alkaloid</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil</style></keyword><keyword><style face="normal" font="default" size="100%">acetylcholinesterase</style></keyword><keyword><style face="normal" font="default" size="100%">cholinergic receptor stimulating agent</style></keyword><keyword><style face="normal" font="default" size="100%">n methyl dextro aspartic acid</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">Blackwell Publishing Inc.</style></publisher><isbn><style face="normal" font="default" size="100%">0002-8614</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Cognitive impairment is a key core feature of schizophrenia. Cognitive deficits start early and affect nearly every individual with schizophrenia. No pharmacological agent to date has been shown to ameliorate cognitive impairment in schizophrenia. Huperzine-A (HupA), an alkaloid initially identified from the Chinese herbal medicine Huperia serrata, is a potent reversible acetyl cholinesterase (AChE) inhibitor with additional unique properties including NMDA-receptor antagonist properties, neuroprotective and antioxidant effects. In animal studies, HupA was shown to possess greater inhibitory, longer-lasting, and more selective effects on AChE activity than donepezil. In clinical studies HupA improved memory, mood, and activities of daily living in patients with Alzheimer&apos;s dementia. Adverse effects have been reported at a very low rate in all the clinical trials, and are mainly cholinergic. Thus, HupA may have beneficial effects not only on cognitive but also functional domains of schizophrenia. Methods: Open label study. Seven subjects with a diagnosis of Schizophrenia and a subjective complaint of memory problems were enrolled. After consent they were asked to take HupA 200 micrograms twice daily for 8 weeks. MATRICS Consensus Cognitive Battery (MCCB) was the primary outcome measure. MATRICS is a brief, individually administered test that helps determine the neuropsychological status of adults ages 20 through 89 who have neurologic injury or disease such as dementia, head injury, and stroke. Other measures of cognition and functional status were collected at the beginning and end of the study. Safety and adverse events were monitored. Results: All patients completed the study. No clinically significant side effects were reported. SPSS 19.0 was used to analyze data. Significant improvement was noted in the Verbal learning domain (Hopkins Verbal Learning Test) (p=0.05) and the overall composite score (p=0.01). Visual learning domain (Brief Visuospatial Memory Test-Revised) improved but did not reach significance (p=0.07). Conclusion: Huperzine-A may improve cognition in subjects with schizophrenia. This pilot study needs to be replicated in a larger study.</style></abstract><notes><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=71038495</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>123</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">123</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pae, C. U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C.-U. Pae, Catholic University of Korea College of Medicine, Bucheon St. Mary&apos;s Hospital, Department of Psychiatry, 2 Sosa-Dong, Wonmi-Gu, Pucheon, Kyounggi-Do 420-717, South Korea. E-mail: pae@catholic.ac.kr</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of the cholinesterase inhibitors in the treatment of schizophrenia</style></title></titles><pages><style face="normal" font="default" size="100%">293-298</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">(Pae) Catholic University of Korea College of Medicine, Bucheon St. Mary&apos;s Hospital, Department of Psychiatry, 2 Sosa-Dong, Wonmi-Gu, Pucheon, Kyounggi-Do 420-717, South Korea</style></number><edition><style face="normal" font="default" size="100%">3</style></edition><keywords><keyword><style face="normal" font="default" size="100%">brain cortex</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibition</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">cognition</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">delusion</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">drug treatment failure</style></keyword><keyword><style face="normal" font="default" size="100%">electroconvulsive therapy</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme activity</style></keyword><keyword><style face="normal" font="default" size="100%">hallucination</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">protein expression</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">schizoaffective psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">*schizophrenia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*schizophrenia/th [Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">acetylcholine/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">choline acetyltransferase/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">cholinergic receptor/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">*cholinesterase inhibitor/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">*cholinesterase inhibitor/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*cholinesterase inhibitor/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">dopamine 1 receptor/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">lurasidone/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">muscarinic receptor/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">neurotransmitter receptor/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin 1A receptor/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin 7 receptor/ec [Endogenous Compound]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">United Kingdom</style></pub-location><publisher><style face="normal" font="default" size="100%">Informa Healthcare (69-77 Paul Street, London EC2A 4LQ, United Kingdom)</style></publisher><isbn><style face="normal" font="default" size="100%">1354-3784</style></isbn><abstract><style face="normal" font="default" size="100%">The effects of cognitive impairment on the occupational functioning, social activity, and economic life of patients with schizophrenia constitute major obstacles to recovery. Currently, the standard biological treatment for schizophrenia consists of antipsychotic medications, which results in significant improvements in psychotic symptoms such as delusions and hallucinations via a high affinity for numerous neurotransmitter receptors. However, the effects of antipsychotics on cognitive dysfunction appear very limited or minimal in clinical practice. In fact, according to recent clinical trials, newer antipsychotics, which have little effect on cholinergic receptors but potent antagonistic effects on the serotonin-7 receptor (5-HT7; e.g., lurasidone), may ameliorate cognitive defects in patients with schizophrenia. It has been consistently reported that both nicotinic and muscarinic receptors play crucial roles in cognition and, thus, that they may be considered potential therapeutic targets for new drugs designed to decrease cognitive deficits. Accordingly, cholinesterase inhibitors (ChEIs) may be effective in enhancing the cognitive functioning of patients with schizophrenia. Not surprisingly, such drugs have been utilized to treat cognitive deficits in patients with schizophrenia in a handful of clinical trials. This paper reviews a brief background information and discusses current clinical issues regarding the use of ChEIs in patients with schizophrenia. 2013 Informa UK, Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Expert Opinion on Investigational Drugs</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013105422</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>91</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">91</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parish, S. L.</style></author><author><style face="normal" font="default" size="100%">Swaine, J. G.</style></author><author><style face="normal" font="default" size="100%">Son, E.</style></author><author><style face="normal" font="default" size="100%">Luken, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Determinants of cervical cancer screening among women with intellectual disabilities: Evidence from medical records</style></title><secondary-title><style face="normal" font="default" size="100%">Public Health Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Public Health Reports</style></full-title></periodical><pages><style face="normal" font="default" size="100%">519-526</style></pages><volume><style face="normal" font="default" size="100%">128</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">adult // aged // article // cancer screening // controlled study // demography // female // gynecologist // health care personnel // human // intellectual impairment // major clinical study // medical record review // multicenter study // obstetrician /</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00915562</style></accession-num><abstract><style face="normal" font="default" size="100%">Objective. We examined receipt of cervical cancer screening and determinants of screening for women with intellectual disabilities in one Southeastern state. Methods. Using medical records data from 2006 through 2010 for community-dwelling women with intellectual disabilities who were 18-65 years of age (n5163), we employed descriptive and bivariate statistics and a multivariate regression model to examine receipt of cervical cancer screening and the determinants of cervical cancer screening across women&apos;s sociodemographic and health-care provider characteristics. Results. Of women 18-65 years of age with intellectual disabilities, 55% received a Papanicolaou (Pap) test during 2008-2010, markedly below the Healthy People 2020 targets or rates of Pap test receipt of women without intellectual disabilities. Women with intellectual disabilities who lived in residential facilities, those who lived in rural communities, and those who had an obstetrician/gynecologist had higher rates of receipt of care than other women with intellectual disabilities. Conclusions. Assertive measures are required to improve the receipt of cervical cancer screening among women with intellectual disabilities. Such measures could include education of women with intellectual disabilities, as well as their paid and family caregivers, and incentives for health-care providers who achieve screening targets. 2013 Association of Schools and Programs of Public Health.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/562/CN-00915562/frame.html</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>121</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">121</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Picon, P. D.</style></author><author><style face="normal" font="default" size="100%">Beltrame, A.</style></author><author><style face="normal" font="default" size="100%">Banta, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P.D. Picon, Department of Internal Medicine-Federal, University of Rio Grande Do sul, Porto Alegre, Brazil. E-mail: paulopicon@gmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">National guidelines for high-cost drugs in brazil: Achievements and constraints of an innovative national evidence-based public health policy</style></title></titles><pages><style face="normal" font="default" size="100%">198-206</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">(Picon) Department of Internal Medicine-Federal, University of Rio Grande Do sul, Porto Alegre, Brazil</style></number><edition><style face="normal" font="default" size="100%">2</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*achievement</style></keyword><keyword><style face="normal" font="default" size="100%">acne/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">acromegaly/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">Addison disease/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">amyotrophic lateral sclerosis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">angioneurotic edema/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">aplastic anemia/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">asthma/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">autoimmune hemolytic anemia/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">Brazil</style></keyword><keyword><style face="normal" font="default" size="100%">celiac disease/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">chronic kidney failure/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">congenital adrenal hyperplasia/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">congenital hypothyroidism/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">Crohn disease/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">cystic fibrosis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">dermatomyositis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes insipidus/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">*drug cost</style></keyword><keyword><style face="normal" font="default" size="100%">dyslipidemia/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">dystonic disorder/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">endometriosis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">epilepsy/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">*evidence based practice</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">Gaucher disease/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">growth hormone deficiency/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">Guillain Barre syndrome/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">*health care policy</style></keyword><keyword><style face="normal" font="default" size="100%">health care system</style></keyword><keyword><style face="normal" font="default" size="100%">hemangioma/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis B/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis C/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperphosphatemia/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">hyperprolactinemia/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">hypoparathyroidism/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">ichthyosis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">idiopathic thrombocytopenic purpura/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">immune deficiency/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">iron overload/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">law</style></keyword><keyword><style face="normal" font="default" size="100%">medical technology</style></keyword><keyword><style face="normal" font="default" size="100%">multiple sclerosis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">myasthenia gravis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">nephrotic syndrome/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">neutropenia/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">osteogenesis imperfecta/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">osteomalacia/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">osteoporosis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">ovary polycystic disease/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">pancreas exocrine insufficiency/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">pancreas insufficiency/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson disease/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">phenylketonuria/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">polymyositis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">*practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">precocious puberty/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">psoriasis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">*public health service</style></keyword><keyword><style face="normal" font="default" size="100%">pure red cell anemia/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">Reiter syndrome/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">renal osteodystrophy/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">rheumatoid arthritis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">rickets/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">sclerosis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">sickle cell anemia/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">spasticity/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">spondylosis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">systemic sclerosis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">Turner syndrome/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">ulcerative colitis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">uterus myoma/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">uveitis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">Wilson disease/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">angiopeptin/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">beclometasone/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">bromocriptine/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">budesonide/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">cabergoline/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">cyclophosphamide/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">cyclosporin/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">danazol/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">dexamethasone/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">fenoterol/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">fludrocortisone/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">flunisolide/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">fluticasone/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">formoterol/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">human immunoglobulin/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">hydrocortisone/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">isotretinoin/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">methylprednisolone/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">octreotide/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">prednisolone/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">prednisone/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">recombinant erythropoietin/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">riluzole/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">salbutamol/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">salmeterol/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">thymocyte antibody/pe [Pharmacoeconomics]</style></keyword><keyword><style face="normal" font="default" size="100%">unindexed drug</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">United States</style></pub-location><publisher><style face="normal" font="default" size="100%">Cambridge University Press (40 West 20th Street, New York NY 10011-4211, United States)</style></publisher><isbn><style face="normal" font="default" size="100%">0266-4623</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: The translation of best evidence into practice has become an important purpose of policy making in health care. In Brazil, a country of continental dimensions with widespread regional and social inequalities, the dissemination and use of the best-evidence in policy making is a critical issue for the healthcare system. Objectives: The main purpose of this study is to describe an evidence-based public health policy with special emphasis on guidelines creation for high-cost medicines. We also describe how that strategy was diffused to the judiciary system and to other parts of the healthcare system. Results: We present an 11-year follow-up of a national project for creating and updating guidelines for high-cost medicines in Brazil. A total of 109 national guidelines were published (new or updated versions) for 66 selected diseases, the first such effort in Brazilian history. The project influenced the Brazilian legislature, which has recently established a Federal Law requiring national guidelines for any new technology listed for payment by the Brazilian public healthcare system. Conclusion: We were able to involve many different stakeholders in a partnership between academia and policy makers, which made possible the widespread dissemination of the clinical practice guidelines. Problems and constraints were also encountered. This evolving public health strategy might be useful for other developing countries. Copyright Cambridge University Press 2013.</style></abstract><notes><style face="normal" font="default" size="100%">International Journal of Technology Assessment in Health Care</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013260853</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>120</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">120</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Posadas, I.</style></author><author><style face="normal" font="default" size="100%">Lopez-Hernandez, B.</style></author><author><style face="normal" font="default" size="100%">Cena, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">V. Cena, Unidad Asociada Neurodeath, Facultad de Medicina, Avda. Almansa, 14, 02006 Albacete, Spain. E-mail: valentin.cena@gmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nicotinic receptors in neurodegeneration</style></title></titles><pages><style face="normal" font="default" size="100%">298-314</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">(Posadas, Lopez-Hernandez, Cena) Unidad Asociada Neurodeath, CSIC-Universidad de Castilla-La Mancha, Departamento de Ciencias Medicas, Albacete, Spain</style></number><edition><style face="normal" font="default" size="100%">3</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer disease</style></keyword><keyword><style face="normal" font="default" size="100%">anxiety disorder</style></keyword><keyword><style face="normal" font="default" size="100%">asthenia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">attention deficit disorder</style></keyword><keyword><style face="normal" font="default" size="100%">behavior disorder</style></keyword><keyword><style face="normal" font="default" size="100%">cognition</style></keyword><keyword><style face="normal" font="default" size="100%">daily life activity</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">disease course</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">epilepsy</style></keyword><keyword><style face="normal" font="default" size="100%">faintness/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Gilles de la Tourette syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">headache/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">muscle spasm/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">nausea/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">nausea and vomiting/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">nerve cell membrane steady potential</style></keyword><keyword><style face="normal" font="default" size="100%">*nerve degeneration</style></keyword><keyword><style face="normal" font="default" size="100%">neuroprotection</style></keyword><keyword><style face="normal" font="default" size="100%">neurotransmitter release</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson disease</style></keyword><keyword><style face="normal" font="default" size="100%">phase 1 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">receptor down regulation</style></keyword><keyword><style face="normal" font="default" size="100%">restlessness/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">rhinopharyngitis/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">somnolence/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">upper respiratory tract infection/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">3 (2,4 dimethoxybenzylidene)anabaseine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">3 (2,4 dimethoxybenzylidene)anabaseine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">3 (2,4 dimethoxybenzylidene)anabaseine</style></keyword><keyword><style face="normal" font="default" size="100%">3 methyl 5 (1 methyl 2 pyrrolidinyl)isoxazole/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">3 methyl 5 (1 methyl 2 pyrrolidinyl)isoxazole/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">3 methyl 5 (1 methyl 2 pyrrolidinyl)isoxazole</style></keyword><keyword><style face="normal" font="default" size="100%">4 aminobutyric acid/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">altinicline</style></keyword><keyword><style face="normal" font="default" size="100%">citicoline</style></keyword><keyword><style face="normal" font="default" size="100%">cotinine</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">dopamine</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine</style></keyword><keyword><style face="normal" font="default" size="100%">glycine receptor/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">ispronicline</style></keyword><keyword><style face="normal" font="default" size="100%">nicotine</style></keyword><keyword><style face="normal" font="default" size="100%">*nicotinic receptor/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">pozanicline/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">pozanicline/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">sofinicline/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">tacrine</style></keyword><keyword><style face="normal" font="default" size="100%">tebanicline/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">Netherlands</style></pub-location><publisher><style face="normal" font="default" size="100%">Bentham Science Publishers B.V. (P.O. Box 294, Bussum 1400 AG, Netherlands)</style></publisher><isbn><style face="normal" font="default" size="100%">1570-159X</style></isbn><abstract><style face="normal" font="default" size="100%">Many studies have focused on expanding our knowledge of the structure and diversity of peripheral and central nicotinic receptors. Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of pentameric ligand-gated ion channels, which include GABA (A and C), serotonin, and glycine receptors. Currently, 9 alpha (alpha2-alpha0) and 3 beta (beta2-beta4) subunits have been identified in the central nervous system (CNS), and these subunits assemble to form a variety of functional nAChRs. The pentameric combination of several alpha and beta subunits leads to a great number of nicotinic receptors that vary in their properties, including their sensitivity to nicotine, permeability to calcium and propensity to desensitize. In the CNS, nAChRs play crucial roles in modulating presynaptic, postsynaptic, and extrasynaptic signaling, and have been found to be involved in a complex range of CNS disorders including Alzheimer&apos;s disease (AD), Parkinson&apos;s disease (PD), schizophrenia, Tourettes syndrome, anxiety, depression and epilepsy. Therefore, there is growing interest in the development of drugs that modulate nAChR functions with optimal benefits and minimal adverse effects. The present review describes the main characteristics of nAChRs in the CNS and focuses on the various compounds that have been tested and are currently in phase I and phase II trials for the treatment of neurodegenerative diseases including PD, AD and age-associated memory and mild cognitive impairment. 2013 Bentham Science Publishers.</style></abstract><notes><style face="normal" font="default" size="100%">Current Neuropharmacology</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013358505</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>99</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">99</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reading, C. L.</style></author><author><style face="normal" font="default" size="100%">Stickney, D. R.</style></author><author><style face="normal" font="default" size="100%">Flores-Riveros, J.</style></author><author><style face="normal" font="default" size="100%">Destiche, D. A.</style></author><author><style face="normal" font="default" size="100%">Ahlem, C. N.</style></author><author><style face="normal" font="default" size="100%">Cefalu, W. T.</style></author><author><style face="normal" font="default" size="100%">Frincke, J. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A synthetic anti-inflammatory sterol improves insulin sensitivity in insulin-resistant obese impaired glucose tolerance subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Obesity</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Obesity</style></full-title></periodical><pages><style face="normal" font="default" size="100%">E343-e349</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">adult // aged // article // body mass // cell stimulation // clinical article // controlled clinical trial // controlled study // cytokine release // double blind procedure // drug efficacy // drug mechanism // drug structure // female // human // human</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">Cn-00913999</style></accession-num><abstract><style face="normal" font="default" size="100%">Objective To study the activity of HE3286 (17alpha-ethynylandrost-5-ene- 3beta,7beta,17beta-triol), an anti-inflammatory sterol that is active in models of obesity-induced inflammation and insulin resistance in high body mass index (BMI) subjects with impaired glucose tolerance (IGT). Design and Methods HE3286 was explored in high BMI IGT subjects using hyperinsulinemic, euglycemic clamp studies. Results In insulin-resistant subjects, HE3286 significantly increased day 29 insulin-stimulated glucose disposal and HDL cholesterol, and decreased C-reactive protein (CRP) compared to placebo. For HE3286, change in M value showed a significant negative correlation with baseline M value. Subjects with baseline M value below the median (4.2 mg/kg/min) had significantly lower adiponectin and higher lipopolysaccharide-stimulated peripheral blood mononuclear cell cytokine secretion. After 28 days of HE3286 treatment, adiponectin levels were significantly increased in insulin-resistant (baseline M &lt; 4.2), but not insulin-sensitive (baseline M &gt; 4.2) subjects, compared to placebo. Conclusions HE3286 significantly increased the frequency of subjects with increased insulin-stimulated glucose disposal and HDL, and decreased CRP compared to placebo, in insulin-resistant, but not insulin-sensitive subjects. Thus, HE3286 may preferentially benefit insulin-resistant, inflamed, high BMI IGT subjects. Copyright 2013 The Obesity Society.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/999/CN-00913999/frame.html</style></url><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1002/oby.20207/asset/oby20207.pdf?v=1&amp;t=hsrm0scb&amp;s=c07131eac5885acc5b0dcc8f61037bc98e81cd22</style></url></related-urls><pdf-urls><url>internal-pdf://3289099772/Reading-2013-A synthetic anti-inf.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/oby.20207</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>73</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">73</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sahu, J. K.</style></author><author><style face="normal" font="default" size="100%">Gulati, S.</style></author><author><style face="normal" font="default" size="100%">Sapra, S.</style></author><author><style face="normal" font="default" size="100%">Arya, R.</style></author><author><style face="normal" font="default" size="100%">Chauhan, S.</style></author><author><style face="normal" font="default" size="100%">Chowdhury, M. R.</style></author><author><style face="normal" font="default" size="100%">Gupta, N.</style></author><author><style face="normal" font="default" size="100%">Kabra, M.</style></author><author><style face="normal" font="default" size="100%">Gupta, Y. K.</style></author><author><style face="normal" font="default" size="100%">Dwivedi, S. N.</style></author><author><style face="normal" font="default" size="100%">Kalra, V.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effectiveness and safety of donepezil in boys with fragile x syndrome: a double-blind, randomized, controlled pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of child neurology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of child neurology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">570-575</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">adolescent // article // autism/di [Diagnosis] // autism/dt [Drug Therapy] // behavior disorder/di [Diagnosis] // behavior disorder/dt [Drug Therapy] // child // controlled clinical trial // controlled study // dose response // double blind procedure //</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00913709</style></accession-num><abstract><style face="normal" font="default" size="100%">The present study was designed as a 12-week, randomized, double-blind, placebo-controlled pilot study to evaluate the effectiveness and safety of donepezil in boys with fragile X syndrome. Twenty boys with fragile X syndrome were randomized to receive 12 weeks of treatment with either placebo or donepezil (2.5 mg daily for initial 4 weeks followed by 5 mg daily for next 8 weeks). The outcome measures included change in intelligence quotient scores on Stanford-Binet Intelligence Scale (Hindi adaptation by Kulshrestha), change in behavioral scores by Conners 3 Parent Rating Scale (Short) and Childhood Autism Rating Scale, safety, and tolerability of donepezil. The study failed to show significant difference in intelligence quotient and behavioral scales with donepezil therapy over 12 weeks. However, donepezil appeared to be safe and well tolerated.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/709/CN-00913709/frame.html</style></url><url><style face="normal" font="default" size="100%">http://jcn.sagepub.com/content/28/5/570.long</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">Pubmed 22752489</style></custom3></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>76</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">76</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sawada, H.</style></author><author><style face="normal" font="default" size="100%">Oeda, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Protocol for a randomised controlled trial: Efficacy of donepezil against psychosis in Parkinson&apos;s disease (EDAP)</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ Open</style></full-title></periodical><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">aggression // article // clinical evaluation // clinical protocol // controlled study // cooperation // delusion // disease severity // double blind procedure // drug efficacy // emotional stress // hallucination // human // informed consent // intentio</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00913803</style></accession-num><abstract><style face="normal" font="default" size="100%">Introduction: Psychosis, including hallucinations and delusions, is one of the important non-motor problems in patients with Parkinson&apos;s disease (PD) and is possibly associated with cholinergic neuronal degeneration. The EDAP (Efficacy of Donepezil against Psychosis in PD) study will evaluate the efficacy of donepezil, a brain acetylcholine esterase inhibitor, for prevention of psychosis in PD. Methods and analysis: Psychosis is assessed every 4 weeks using the Parkinson Psychosis Questionnaire (PPQ) and patients with PD whose PPQ-B score (hallucinations) and PPQ-C score (delusions) have been zero for 8 weeks before enrolment are randomised to two arms: patients receiving donepezil hydrochloride or patients receiving placebo. The patients are then followed for 96 weeks. The primary outcome measure is the time to the event, defined as getting 2 points or more on the PPQ-B score or PPQ-C score, which is assessed using a survival time analysis. The hypothesis being tested is that donepezil prevents psychosis in patients with PD. Efficacy will be tested statistically using the intention-to-treat analysis including a log-rank test or Cox proportional hazard models. Secondary outcomes, such as changes of PPQ scores and Unified Parkinson&apos;s Disease Rating Scale scores from baseline will be assessed. Ethics and dissemination: Ethics approval was received from the Central Review Board of the National Hospital Organization, Tokyo, Japan. The trial was declared and registered to the Pharmaceuticals and Medical Devices Agency(PMDA), Japan (No. 22-4018). All participants will receive a written informed consent that was approved by the Central Review. A completed written informed consent is required to enrol in the study. Severe adverse events will be monitored by investigators and in cases where a severe adverse event was previously unreported, it will be reported to the PMDA.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/803/CN-00913803/frame.html</style></url><url><style face="normal" font="default" size="100%">http://bmjopen.bmj.com/content/3/9/e003533.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1129566413/Sawada-2013-Protocol for a rando.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1136/bmjopen-2013-003533</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>77</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">77</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmitt, F. A.</style></author><author><style face="normal" font="default" size="100%">Saxton, J.</style></author><author><style face="normal" font="default" size="100%">Ferris, S. H.</style></author><author><style face="normal" font="default" size="100%">MacKell, J.</style></author><author><style face="normal" font="default" size="100%">Sun, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. The full SIB in moderate to severe Alzheimer&apos;s disease patients participating in a donepezil study</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1050-1056</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer disease/dt [Drug Therapy] // article // clinical article // clinical practice // controlled study // disease severity // dose response // drug effect // drug efficacy // drug megadose // female // functional assessment // human // instrument v</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00913933</style></accession-num><abstract><style face="normal" font="default" size="100%">Aim The Severe Impairment Battery (SIB), a reliable cognitive measure for evaluating treatment response in advanced Alzheimer&apos;s disease (AD), takes approximately 20 min to administer. A recently derived 8-item version of the SIB - the SIB-8 - which takes about 3 min to administer, may represent a more convenient tool for use in clinical practice. The current analyses further explored the SIB-8 scale with respect to its validity and sensitivity. Methods A post hoc analysis was performed using data from a 24-week trial of donepezil 23 mg/day and 10 mg/day in &gt; 1400 patients with moderate to severe AD [baseline Mini-Mental State Examination (MMSE) score 0-20]. Treatment effects on cognition (patterns of score change) were assessed using the full SIB and SIB-8 in the total study population and subgroups based on concomitant memantine use and baseline MMSE. Internal consistency/agreement and correlations between the SIB and SIB-8 and other clinical end points were evaluated. Results Assessment of score changes from baseline to week 24 with donepezil (23 or 10 mg/day) demonstrated comparable patterns of change when using the SIB-8 and the full SIB, despite inherent differences in the total score ranges for the two scales. Internal consistency/agreement between the full SIB and SIB-8 was good (Cronbach&apos;s alphas: 0.77-0.95). SIB-8 scores reliably correlated with SIB total scores (r = 0.859, baseline; r = 0.900, week 24; p &lt; 0.0001), as well as MMSE scores (r = 0.7163, baseline; r = 0.7963, week 24; p &lt; 0.0001). Scores on both SIB scales were moderately associated with functional measures at baseline and week 24. Conclusions In this post hoc analysis, similar treatment effects were measured by the full SIB and the SIB-8. Very good internal consistency/agreement and strong correlations between the SIB and the more rapid and convenient SIB-8 indicate that the SIB-8 may be a useful and efficient clinical proxy for the full SIB in evaluating treatment response in patients with advanced AD. 2013 John Wiley &amp; Sons Ltd.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/933/CN-00913933/frame.html</style></url><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1111/ijcp.12188/abstract?systemMessage=Wiley+Online+Library+will+be+disrupted+Saturday%2C+15+March+from+10%3A00-12%3A00+GMT+%2806%3A00-08%3A00+EDT%29+for+essential+maintenance</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/ijcp.12188</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>104</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">104</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sequeira, P. A.</style></author><author><style face="normal" font="default" size="100%">Montoya, L.</style></author><author><style face="normal" font="default" size="100%">Ruelas, V.</style></author><author><style face="normal" font="default" size="100%">Xing, D.</style></author><author><style face="normal" font="default" size="100%">Chen, V.</style></author><author><style face="normal" font="default" size="100%">Beck, R.</style></author><author><style face="normal" font="default" size="100%">Peters, A. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Continuous glucose monitoring pilot in low-income type 1 diabetes patients</style></title><secondary-title><style face="normal" font="default" size="100%">Diabetes Technology and Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Diabetes Technology and Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">855-858</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">adult // aged // article // blood glucose monitoring // clinical article // continuous glucose monitoring // controlled study // crossover procedure // educational status // female // glucose blood level // Hispanic // human // insulin dependent diabete</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00914336</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Continuous glucose monitoring (CGM) has been shown to be a valuable tool to improve glycemic control in patients with diabetes. The objective of this pilot study was to develop and implement CGM in an existing diabetes clinic for low-income patients on multiple daily injections. Subjects and Methods: This was a single-center, prospective, randomized controlled, crossover pilot study. Initial focus groups were held to create low-literacy, Spanish and English guides to the use of carbohydrate counting and CGM. These tools were implemented to train participants on carbohydrate counting and insulin adjustments participants. Subjects were then randomized to start in Group A (CGM) or Group B (self-monitoring blood glucose and then switched after 28 weeks). Hemoglobin A1c (HbA1c) was obtained at baseline and at the end of both study phases. Results: Twenty-five economically challenged, primarily Latino participants with minimal prior education on intensive diabetes management completed the study. No significant reduction in HbA1c or decrease in time spent in parameters of low and high blood glucose was shown. However, eighty percent of participants who completed the study wanted to continue to use CGM once the research study was over. The participants also felt that the CGM made adjusting insulin easier. Conclusions: CGM can be implemented in patients from a low-income public clinic; however, HbA1c reduction was not achieved. Given the underlying lack of baseline self-management knowledge, a longer trial might be necessary to see benefit with CGM in this population. 2013 Mary Ann Liebert, Inc.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/336/CN-00914336/frame.html</style></url><url><style face="normal" font="default" size="100%">http://online.liebertpub.com/doi/abs/10.1089/dia.2013.0072?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed&amp;</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1089/dia.2013.0072</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>113</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">113</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Skripka-Serry, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. Skripka-Serry, Bioassociat, Israel</style></auth-address><titles><title><style face="normal" font="default" size="100%">The great neuro-pipeline &apos;brain drain&apos; (and why Big Pharma hasn&apos;t given up on CNS disorders)</style></title></titles><pages><style face="normal" font="default" size="100%">9-16</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">(Skripka-Serry) Bioassociat, Israel</style></number><edition><style face="normal" font="default" size="100%">4</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer disease/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">amyotrophic lateral sclerosis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">autism/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">autism/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">bipolar disorder/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">bipolar disorder/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">blindness/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">blindness/su [Surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">*central nervous system disease</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular accident/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">chronic pain/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">chronic pain/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">chronic pain/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">cluster headache/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">depression/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">depression/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">depression/th [Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">drug industry</style></keyword><keyword><style face="normal" font="default" size="100%">drug treatment failure</style></keyword><keyword><style face="normal" font="default" size="100%">epilepsy/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">epilepsy/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">epilepsy/su [Surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">head injury/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">health care cost</style></keyword><keyword><style face="normal" font="default" size="100%">hearing aid</style></keyword><keyword><style face="normal" font="default" size="100%">hearing impairment/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">migraine/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">migraine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">multiple sclerosis/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">neurosurgery</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson disease/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">placebo effect</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">retinal implant</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">spinal cord injury/dm [Disease Management]</style></keyword><keyword><style face="normal" font="default" size="100%">transcranial magnetic stimulation</style></keyword><keyword><style face="normal" font="default" size="100%">vagus nerve stimulation</style></keyword><keyword><style face="normal" font="default" size="100%">anticonvulsive agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressant agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">atypical antipsychotic agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">beta secretase 1</style></keyword><keyword><style face="normal" font="default" size="100%">beta secretase inhibitor/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">beta1a interferon/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">botulinum toxin A/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">carbamazepine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">ergotamine derivative/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">gantenerumab/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">lamotrigine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">lithium/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">memantine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">mk 8931/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">mood stabilizer/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">noradrenalin uptake inhibitor/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">pramipexole/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin noradrenalin reuptake inhibitor/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin uptake inhibitor/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">solanezumab</style></keyword><keyword><style face="normal" font="default" size="100%">spi 1865/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">steroid/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">topiramate/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">unindexed drug</style></keyword><keyword><style face="normal" font="default" size="100%">valproic acid/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">vigabatrin/dt [Drug Therapy]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">United Kingdom</style></pub-location><publisher><style face="normal" font="default" size="100%">RJ Communications and Media Ltd. (39 Vineyard Path, Mortlake London SW14 8ET, United Kingdom)</style></publisher><isbn><style face="normal" font="default" size="100%">1469-4344</style></isbn><abstract><style face="normal" font="default" size="100%">Central Nervous System (CNS) disorders bear an economic burden of more than $2 trillion in the US and EU and rake in upwards of $80 billion a year for the pharmaceutical industry. Yet they have become as much a vice as a potential virtue. A novel Alzheimer&apos;s disease (AD) medication bears every promise of outshining the likes of Lipitor in blockbuster status, but its chances of reaching the market are also nearly 50% lower, and development costs 30% higher, than those of its cardiovascular counterpart.</style></abstract><notes><style face="normal" font="default" size="100%">Drug Discovery World</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013704209</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>86</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">86</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sole-Padulles, Cristina</style></author><author><style face="normal" font="default" size="100%">Bartres-Faz, David</style></author><author><style face="normal" font="default" size="100%">Llado, Albert</style></author><author><style face="normal" font="default" size="100%">Bosch, Beatriz</style></author><author><style face="normal" font="default" size="100%">Pena-Gomez, Cleofe</style></author><author><style face="normal" font="default" size="100%">Castellvi, Magdalena</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer&apos;s disease</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of clinical psychopharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of clinical psychopharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">199-205</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Sr-dementia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">Cn-00863286</style></accession-num><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/286/CN-00863286/frame.html</style></url><url><style face="normal" font="default" size="100%">http://graphics.tx.ovid.com/ovftpdfs/FPDDNCMCNAOBDB00/fs046/ovft/live/gv025/00004714/00004714-201304000-00009.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3130390644/Sole-Padulles-2013-Donepezil treatment.pdf</url></pdf-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>75</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">75</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Song, H. R.</style></author><author><style face="normal" font="default" size="100%">Woo, Y. S.</style></author><author><style face="normal" font="default" size="100%">Wang, H. R.</style></author><author><style face="normal" font="default" size="100%">Jun, T. Y.</style></author><author><style face="normal" font="default" size="100%">Bahk, W. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep</style></title><secondary-title><style face="normal" font="default" size="100%">International Clinical Psychopharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Clinical Psychopharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">346-348</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">adult // aged // Alzheimer disease/dt [Drug Therapy] // article // body mass // Clinical Dementia Rating // controlled study // daytime somnolence // dosage schedule comparison // evening dosage // female // human // major clinical study // male // Mini</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00913979</style></accession-num><abstract><style face="normal" font="default" size="100%">Many patients with Alzheimer&apos;s disease experience sleep disturbances, and donepezil is usually prescribed for night-time administration. However, increased acetylcholine is associated with cortical arousal. We evaluated whether subjective sleep quality differed according to the timing of medication administration. Ninety-two patients with mild to moderate Alzheimer&apos;s disease who had taken donepezil at night (n=54) or galantamine in the morning (n=38) were recruited for this study. Scores on the sleep visual analogue scale (VAS) for sleep quality and daytime drowsiness were obtained. The mean sleep-quality and daytime-drowsiness VAS scores of the donepezil and galantamine groups differed significantly at baseline (44.0+/-26.4 vs. 55.2+/-27.3, respectively; P&lt;0.001 and 48.8+/-28.8 vs. 38.8+/-25.3, respectively; P&lt;0.001). The patients taking donepezil were then randomly assigned to take donepezil in the morning (n=24) or at night (n=30). Eight weeks later, VAS scores also differed among the three groups (P&lt;0.001 for both sleep quality and daytime drowsiness). The VAS scores of patients taking galantamine and donepezil in the morning were different from those taking donepezil at night at week 8. Significant changes in VAS scores emerged only in the group taking donepezil in the morning (4.6+/-26.5, P=0.046 for sleep quality; -7.1+/-26.1, P&lt;0.001 for daytime drowsiness). These results suggest that taking acetylcholinesterase inhibitors in the morning can improve the sleep states of patients with Alzheimer&apos;s disease. 2013 Wolters Kluwer Health | Lippincott Williams &amp; Wilkins.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/979/CN-00913979/frame.html</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1097/YIC.0b013e328364f58d</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>110</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">110</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sugarman, P.</style></author><author><style face="normal" font="default" size="100%">Mitchell, A.</style></author><author><style face="normal" font="default" size="100%">Frogley, C.</style></author><author><style face="normal" font="default" size="100%">Dickens, G. L.</style></author><author><style face="normal" font="default" size="100%">Picchioni, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Picchioni, St Andrew&apos;s Healthcare, St Andrew&apos;s Academic Centre, Billing Road, Northampton, NN1 5BW, United Kingdom. E-mail: mpicchioni@standrew.co.uk</style></auth-address><titles><title><style face="normal" font="default" size="100%">Off-licence prescribing and regulation in psychiatry: Current challenges require a new model of governance</style></title></titles><pages><style face="normal" font="default" size="100%">233-243</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">(Picchioni) St Andrew&apos;s Healthcare, St Andrew&apos;s Academic Centre, Billing Road, Northampton, NN1 5BW, United Kingdom</style></number><edition><style face="normal" font="default" size="100%">4</style></edition><keywords><keyword><style face="normal" font="default" size="100%">aggression</style></keyword><keyword><style face="normal" font="default" size="100%">agitation</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bipolar disorder/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">child psychiatry</style></keyword><keyword><style face="normal" font="default" size="100%">clinical effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">clinical practice</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">drug approval</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug research</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">general practitioner</style></keyword><keyword><style face="normal" font="default" size="100%">*health care quality</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">intellectual impairment</style></keyword><keyword><style face="normal" font="default" size="100%">*licence</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">mania/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">mental health care</style></keyword><keyword><style face="normal" font="default" size="100%">monoaminergic system</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">*off label drug use</style></keyword><keyword><style face="normal" font="default" size="100%">open study</style></keyword><keyword><style face="normal" font="default" size="100%">patient monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">patient safety</style></keyword><keyword><style face="normal" font="default" size="100%">posttraumatic stress disorder/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*prescription</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">*psychiatry</style></keyword><keyword><style face="normal" font="default" size="100%">QT prolongation/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">risk management</style></keyword><keyword><style face="normal" font="default" size="100%">schizoaffective psychosis/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">seizure/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">suicidal behavior/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">agomelatine/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">amitriptyline/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">anticonvulsive agent/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">carbamazepine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">diazepam</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">galantamine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">lorazepam</style></keyword><keyword><style face="normal" font="default" size="100%">mirtazapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">paroxetine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">phenelzine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">*psychotropic agent</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">rivastigmine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin uptake inhibitor/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">valproic acid/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">ziprasidone/ae [Adverse Drug Reaction]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">United Kingdom</style></pub-location><publisher><style face="normal" font="default" size="100%">SAGE Publications Ltd (55 City Road, London EC1Y 1SP, United Kingdom)</style></publisher><isbn><style face="normal" font="default" size="100%">2045-1253</style></isbn><abstract><style face="normal" font="default" size="100%">The growing worldwide use of pharmaceuticals is managed in some countries by a regulatory system which sharply divides legal use into licensed and unlicensed categories. We examine how for the range of psychotropics this simultaneously restricts the possible benefits to patients, prescribers and producers in some domains, while failing to manage the risks in others. A more flexible system, which shares at an earlier stage experience and evidence on benefits and risks in patients, previously marginalized on the grounds of age, diagnosis or comorbidity, would aid the development of safer, more effective &apos;real-world prescribing&apos;. Practical recommendations are made for a new model of research and prescribing governance, to enable more effective repurposing of these treatments. The Author(s), 2013.</style></abstract><notes><style face="normal" font="default" size="100%">Therapeutic Advances in Psychopharmacology</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013787816</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>78</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">78</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tariot, P. N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer&apos;s disease compared to continuation of donepezil or addition or substitution of memantine</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">62-63</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">add on therapy // Alzheimer disease/dt [Drug Therapy] // behavior // clinical decision making // clinical protocol // cognition // controlled study // daily life activity // double blind procedure // drug substitution // drug withdrawal // follow up //</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00908503</style></accession-num><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/503/CN-00908503/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ebm.bmj.com/content/18/2/62.long</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1136/eb-2012-100722</style></electronic-resource-num></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>106</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">106</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thakurathi, Neelam</style></author><author><style face="normal" font="default" size="100%">Vincenzi, Brenda</style></author><author><style face="normal" font="default" size="100%">Henderson, David C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia</style></title><secondary-title><style face="normal" font="default" size="100%">Expert opinion on investigational drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert opinion on investigational drugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">259-65</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Binding Sites</style></keyword><keyword><style face="normal" font="default" size="100%">Cholinesterase Inhibitors/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Cholinesterase Inhibitors/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">Cholinesterase Inhibitors/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">*Cholinesterase Inhibitors/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">*Cognition Disorders/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders/px [Psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Indans/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Indans/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">Indans/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">*Indans/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Molecular</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Structure</style></keyword><keyword><style face="normal" font="default" size="100%">Piperidines/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperidines/ch [Chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperidines/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">*Piperidines/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default" size="100%">Schizophrenia/co [Complications]</style></keyword><keyword><style face="normal" font="default" size="100%">*Schizophrenia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Schizophrenic Psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">England</style></pub-location><publisher><style face="normal" font="default" size="100%">Massachusetts General Hospital, Schizophrenia Clinical and Research Program, Boston, MA, USA.</style></publisher><isbn><style face="normal" font="default" size="100%">1744-7658</style></isbn><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Even though cognitive impairment is manifested in almost all patients with schizophrenia, the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) study showed no significant difference between first- and second-generation psychotropic drugs in improving cognitive abilities. Discovering new drugs that can improve impaired cognition, thus, is an attractive treatment target for patients with schizophrenia., AREAS COVERED: This article briefly reviews about donepezil, a highly selective (IC(50) = 6.7 nM) centrally acting reversible acetylcholinesterase inhibitor that has been approved by FDA for treating cognitive deficit states such as in Alzheimer&apos;s disease and its uses in clinical trials for the treatment of schizophrenia. The literature search included PubMed and Cochrane library with the following words: donepezil, schizophrenia and cognitive impairments., EXPERT OPINION: The results of several clinical trials utilizing donepezil as an adjunct to second-generation antipsychotic drugs targeting cognitive deficits in schizophrenia subjects have been disappointing and would not lead clinicians to consider this as a potential treatment option. While longer randomized controlled trials, increase dosage and selected groups of patients at different stage of cognitive impairment may provide a better understanding of the potential for this drug in addressing cognitive deficits, results to date have not been encouraging.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=medl&amp;NEWS=N&amp;AN=23215841</style></url><url><style face="normal" font="default" size="100%">http://informahealthcare.com/doi/abs/10.1517/13543784.2013.750650</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>126</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">126</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thakurathi, N.</style></author><author><style face="normal" font="default" size="100%">Vincenzi, B.</style></author><author><style face="normal" font="default" size="100%">Henderson, D. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D.C. Henderson, Harvard Medical School, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, United States. E-mail: dchenderson@partners.org</style></auth-address><titles><title><style face="normal" font="default" size="100%">Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia</style></title></titles><pages><style face="normal" font="default" size="100%">259-265</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">(Thakurathi, Vincenzi, Henderson) Massachusetts General Hospital, Schizophrenia Clinical and Research Program, Boston, MA, United States</style></number><edition><style face="normal" font="default" size="100%">2</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Alzheimer disease/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">attention</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">*cognitive defect/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">crystal structure</style></keyword><keyword><style face="normal" font="default" size="100%">drug approval</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose increase</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">executive function</style></keyword><keyword><style face="normal" font="default" size="100%">food and drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">IC 50</style></keyword><keyword><style face="normal" font="default" size="100%">learning</style></keyword><keyword><style face="normal" font="default" size="100%">liver toxicity/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">*schizophrenia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">short term memory</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">verbal memory</style></keyword><keyword><style face="normal" font="default" size="100%">visual memory</style></keyword><keyword><style face="normal" font="default" size="100%">working memory</style></keyword><keyword><style face="normal" font="default" size="100%">aripiprazole/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*donepezil/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">*donepezil/do [Drug Dose]</style></keyword><keyword><style face="normal" font="default" size="100%">*donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*donepezil/po [Oral Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">*donepezil/pk [Pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">fluphenazine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">pimozide/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">tacrine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">tacrine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">tacrine/to [Drug Toxicity]</style></keyword><keyword><style face="normal" font="default" size="100%">ziprasidone/dt [Drug Therapy]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">United Kingdom</style></pub-location><publisher><style face="normal" font="default" size="100%">Informa Healthcare (69-77 Paul Street, London EC2A 4LQ, United Kingdom)</style></publisher><isbn><style face="normal" font="default" size="100%">1354-3784</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Even though cognitive impairment is manifested in almost all patients with schizophrenia, the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) study showed no significant difference between first- and second-generation psychotropic drugs in improving cognitive abilities. Discovering new drugs that can improve impaired cognition, thus, is an attractive treatment target for patients with schizophrenia. Areas covered: This article briefly reviews about donepezil, a highly selective (IC50 = 6.7 nM) centrally acting reversible acetylcholinesterase inhibitor that has been approved by FDA for treating cognitive deficit states such as in Alzheimer&apos;s disease and its uses in clinical trials for the treatment of schizophrenia. The literature search included PubMed and Cochrane library with the following words: donepezil, schizophrenia and cognitive impairments. Expert opinion: The results of several clinical trials utilizing donepezil as an adjunct to second-generation antipsychotic drugs targeting cognitive deficits in schizophrenia subjects have been disappointing and would not lead clinicians to consider this as a potential treatment option. While longer randomized controlled trials, increase dosage and selected groups of patients at different stage of cognitive impairment may provide a better understanding of the potential for this drug in addressing cognitive deficits, results to date have not been encouraging. 2012 Informa UK, Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Expert Opinion on Investigational Drugs</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2013029425</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>108</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">108</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vingerhoets, W. A. M.</style></author><author><style face="normal" font="default" size="100%">Bloemen, O. J. N.</style></author><author><style face="normal" font="default" size="100%">Bakker, G.</style></author><author><style face="normal" font="default" size="100%">van Amelsvoort, T. A. M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">W.A.M. Vingerhoets, Department of Psychiatry and Psychology, Maastricht University, Vijverdalseweg 1, Maastricht 6226 NB, Netherlands. E-mail: claudia.vingerhoets@maastrichtuniversity.nl</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pharmacological interventions for the MATRICS cognitive domains in schizophrenia: What&apos;s the evidence?</style></title></titles><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">(Vingerhoets, Bloemen, Bakker, van Amelsvoort) Department of Psychiatry and Psychology, Maastricht University, Maastricht, Netherlands</style></number><edition><style face="normal" font="default" size="100%">DEC</style></edition><keywords><keyword><style face="normal" font="default" size="100%">alertness</style></keyword><keyword><style face="normal" font="default" size="100%">attention</style></keyword><keyword><style face="normal" font="default" size="100%">cognition</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">information processing</style></keyword><keyword><style face="normal" font="default" size="100%">learning</style></keyword><keyword><style face="normal" font="default" size="100%">memory consolidation</style></keyword><keyword><style face="normal" font="default" size="100%">neuropharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">problem solving</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">*schizophrenia/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">social cognition</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">working memory</style></keyword><keyword><style face="normal" font="default" size="100%">amisulpride/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">amisulpride/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">amisulpride/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">amisulpride/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">aripiprazole/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">aripiprazole/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">aripiprazole/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">aripiprazole/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">aripiprazole/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">bl 1020/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">bl 1020/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">bl 1020/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">bl 1020/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">chlorprothixene/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">chlorprothixene/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">chlorprothixene/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">chlorprothixene/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">citalopram/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">citalopram/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">citalopram/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">clozapine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">dexamphetamine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">dexamphetamine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">dexamphetamine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">dihydrexidine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">dihydrexidine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">dihydrexidine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">flupentixol/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">flupentixol/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">flupentixol/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">flupentixol/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">fluphenazine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">fluphenazine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">fluphenazine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">fluphenazine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">fluvoxamine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">fluvoxamine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">fluvoxamine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">ispronicline/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">ispronicline/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">ispronicline/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">loxapine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">loxapine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">loxapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">loxapine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">ondansetron/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">ondansetron/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">ondansetron/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">paliperidone/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">paliperidone/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">paliperidone/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">paliperidone/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">perazine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">perazine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">perazine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">perazine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">perospirone/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">perospirone/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">perospirone/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">perospirone/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">risperidone/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin 2A antagonist/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin 2A antagonist/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin 2A antagonist/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin 2A antagonist/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">sertindole/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">sertindole/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">sertindole/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">sertindole/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">tandospirone/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">tandospirone/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">tandospirone/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">tropisetron/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">tropisetron/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">tropisetron/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">unindexed drug</style></keyword><keyword><style face="normal" font="default" size="100%">ziprasidone/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">ziprasidone/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">ziprasidone/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">zuclopenthixol/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">zuclopenthixol/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">zuclopenthixol/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">zuclopenthixol/pd [Pharmacology]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><pub-location><style face="normal" font="default" size="100%">Switzerland</style></pub-location><publisher><style face="normal" font="default" size="100%">Frontiers Media SA (EPFL Innovation Square, Building I, Lausanne CH-1015, Switzerland)</style></publisher><abstract><style face="normal" font="default" size="100%">Schizophrenia is a disabling, chronic psychiatric disorder with a prevalence rate of 0.5-1% in the general population. Symptoms include positive (e.g., delusions, hallucinations), negative (e.g., blunted affect, social withdrawal), as well as cognitive symptoms (e.g., memory and attention problems). Although 75-85% of patients with schizophrenia report cognitive impairments, the underlying neuropharmacological mechanisms are not well understood and currently no effective treatment is available for these impairments. This has led to the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative, which established seven cognitive domains that are fundamentally impaired in schizophrenia. These domains include verbal learning and memory, visual learning and memory, working memory, attention and vigilance, processing speed, reasoning and problem solving, and social cognition. Recently, a growing number of studies have been conducted trying to identify the underlying neuropharmacological mechanisms of cognitive impairments in schizophrenia patients. Specific cognitive impairments seem to arise from different underlying neuropharmacological mechanisms. However, most review articles describe cognition in general and an overview of the mechanisms involved in these seven separate cognitive domains is currently lacking. Therefore, we reviewed the underlying neuropharmacological mechanisms focusing on the domains as established by the MATRICS initiative which are considered most crucial in schizophrenia. 2013 Vingerhoets, Bloemen, Bakker and van Amelsvoort.</style></abstract><notes><style face="normal" font="default" size="100%">Frontiers in Psychiatry</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.frontiersin.org/Journal/FullText.aspx?ART_DOI=10.3389/fpsyt.2013.00157&amp;x=y#h17</style></url><url><style face="normal" font="default" size="100%">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=emed11&amp;NEWS=N&amp;AN=2014015241</style></url></related-urls></urls></record><record><database name="Donepezil_from2013.enl" path="/Users/eduardogonzalezfraile/Desktop/Donepezil/Donepezil_from2013.enl">Donepezil_from2013.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>100</rec-number><foreign-keys><key app="EN" db-id="095e2vwfkx0zxgez0rmve2wn2wvdvwve2ar5">100</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wong, K. L.</style></author><author><style face="normal" font="default" size="100%">Lee, K. B. L.</style></author><author><style face="normal" font="default" size="100%">Tai, B. C.</style></author><author><style face="normal" font="default" size="100%">Law, P.</style></author><author><style face="normal" font="default" size="100%">Lee, E. H.</style></author><author><style face="normal" font="default" size="100%">Hui, J. H. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: A prospective, randomized controlled clinical trial with 2 years&apos; follow-up</style></title><secondary-title><style face="normal" font="default" size="100%">Arthroscopy - Journal of Arthroscopic and Related Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Arthroscopy - Journal of Arthroscopic and Related Surgery</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2020-2028</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">adult // article // body mass // controlled study // female // follow up // hematopoietic stem cell // hematopoietic stem cell transplantation // human // human cell // joint mobility // knee osteoarthritis/dt [Drug Therapy] // knee osteoarthritis/su [S</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00911279</style></accession-num><abstract><style face="normal" font="default" size="100%">Purpose To analyze the results of the use of intra-articular cultured autologous bone marrow-derived mesenchymal stem cell (MSC) injections in conjunction with microfracture and medial opening-wedge high tibial osteotomy (HTO). Methods Fifty-six knees in 56 patients with unicompartmental osteoarthritic knees and genu varum were randomly allocated to the cell-recipient group (n = 28) or control group (n = 28). Patients who had a joint line congruity angle of more than 2, malalignment of the knee from femoral causes, a fixed flexion deformity, or age older than 55 years were excluded. All patients underwent HTO and microfracture. The cell-recipient group received intra-articular injection of cultured MSCs with hyaluronic acid 3 weeks after surgery, whereas the control group only received hyaluronic acid. The primary outcome measure was the International Knee Documentation Committee (IKDC) score at intervals of 6 months, 1 year, and 2 years postoperatively. Secondary outcome measures were Tegner and Lysholm clinical scores and 1-year postoperative Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scores. Results The median age of the patients was 51 years, with a mean body mass index of 23.85. Both treatment arms achieved improvements in Tegner, Lysholm, and IKDC scores. After adjustment for age, baseline scores, and time of evaluation, the cell-recipient group showed significantly better scores. The effect of treatment showed an added improvement of 7.65 (95% confidence interval [CI], 3.04 to 12.26; P =.001) for IKDC scores, 7.61 (95% CI, 1.44 to 13.79; P =.016) for Lysholm scores, and 0.64 (95% CI, 0.10 to 1.19; P =.021) for Tegner scores. Magnetic resonance imaging scans performed 1 year after surgical intervention showed significantly better MOCART scores for the cell-recipient group. The age-adjusted mean difference in MOCART score was 19.6 (95% CI, 10.5 to 28.6; P &lt;.001). Conclusions Intra-articular injection of cultured MSCs is effective in improving both short-term clinical and MOCART outcomes in patients undergoing HTO and microfracture for varus knees with cartilage defects. Level of Evidence Level II, randomized controlled trial. 2013 by the Arthroscopy Association of North America.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/279/CN-00911279/frame.html</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.arthro.2013.09.074</style></electronic-resource-num></record></records></xml>